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Abstract
Objective Rheumatoid arthritis (RA) is an autoimmune
disease that targets the synovium. The autoantigens
involved in the autoantibody responses in RA are unknown.
A targeted proteomics approach was used to identify
proteins in RA synovial fluid (SF) that are recognized by
autoantibodies in RA sera.
Methods RA SF, depleted of abundant proteins, was
fractionated by two-dimensional liquid chromatography
(chromatofocusing followed by reverse phase HPLC).
Protein arrays constructed from these fractions were probed
with RA and normal control sera, and proteins within
reactive fractions were identified by mass spectrometry.
The reactivity of RA sera to an identified peptide was
confirmed by ELISA.
Results RA sera specifically reacted to a SF fraction
containing fibrin. Mass spectrometry analyses established
the presence of a citrullinated arginine at position 271 of the
fibrin fragment present in RA SF. A synthetic peptide
corresponding to fibrin residues 259–287, containing the
citrulline substitution at Arg 271, was recognized by 10 of
12 RA sera, but by two of 18 normal control sera and one
of 10 systemic lupus erythematosus sera.
Conclusion Proteomics methodology can be used to directly
characterize post-translational modifications in candidate
autoantigens isolated from sites of disease activity. The
finding that RA sera contain antibodies to the citrullinated
fibrin 259–287 peptide may ultimately lead to improved
diagnostic tests for RA and/or biomarkers for disease activity.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease that
targets the joints and affects 0.8% of the adults worldwide
[1, 2]. Chronic joint inflammation leads to cartilage and
bone destruction, resulting in loss of function. Many self-
antigens have been implicated in the triggering and/or
maintenance of autoreactive lymphocyte responses in RA
[3–5]. Nevertheless, there remains an uncertainty as to how
disease is caused and maintained [6]. Aberrant post-
translational modifications of self-proteins may play a role
in breaking T and B cell tolerance, leading to autoimmunity
[7–9]. Of particular interest to the clinical management of
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RA are the anti-citrulline antibodies [10], which can predict
both development [11, 12] and severity of disease [13, 14].
Citrullination is the post-translational modification (deimi-
nation) of arginine to citrulline catalyzed by protein arginyl
deiminase (PAD) enzymes [15]. This conversion changes
the charge of the site from a positive to a neutral and
increases the mass of the amino acid by 1 Da. The
difference in charge may cause protein unfolding [16],
thereby exposing novel epitopes.
The current diagnostic test for anti-citrulline anti-
bodies employs a cyclic citrullinated peptide (CCP), yet
the citrulline residues on synovial joint proteins that are
target(s) of anti-citrulline antibodies in vivo have not
been precisely defined. Autoantigens, which exist in
citrullinated forms include fibrinogen [17–19] (which
was initially thought to be filaggrin [20, 21]), vimentin
[22–24], collagen type I [25, 26], collagen type II [26–
28], fibronectin [29], and alpha-enolase [30]. The
presence of citrulline-modified fibrinogen alpha (FIBA)
and beta chains in RA synovial tissue or fluid has been
reported [17, 19].
The goal of this project was to develop a method to
discover novel RA autoantigens using a targeted proteomic
analysis. We and others have reasoned that autoantigens
might be enriched in RA SF and specifically recognized by
autoantibodies in RA sera. Previous autoantigen and
biomarker discovery projects have employed one of several
approaches to fractionate biological sample preparations,
including two-dimensional PAGE, miniaturized chips with
diverse surfaces to promote differential protein binding, and
multidimensional LC–MS/MS [31]. Often these fraction-
ation approaches were combined with immunoblotting with
patient sera. Although they yielded some novel informa-
tion, such methods were complicated by the wide dynamic
range of protein concentrations in serum and SF, which
obscures identification of potentially informative proteins in
minor abundance.
To separate and probe SF proteins, we used a method that
was previously used to characterize cancer antigens [32],
which included two-dimensional liquid chromatography,
protein arrays, and high-resolution mass spectrometry.
Depletion of abundant serum proteins followed by protein
fractionation via two-dimensional liquid chromatography
increased the likelihood of identifying the lower abundance
proteins. Protein arrays constructed from fractionated SF
were probed with RA and control sera to identify biologi-
cally significant fractions, and further analyses were
performed only on those targeted fractions. It is important
to note that the arrays were constructed from clinical samples
that contain proteins with their post-translational modifica-
tions acquired in vivo. Liquid chromatography–tandem mass
spectrometry (LC–MS/MS) was then used to identify
immunogenic protein fragments and their post-translational
modifications. Through this targeted proteomics approach,
we have identified a citrulline-modified Arg 271 residue,
within a fibrin alphaC domain fragment stably present in RA
SF, as a target of autoantibodies in RA sera.
Materials and Methods
Patient Samples
All samples were obtained using IRB approved protocols
and all patients consented to be part of the study. SF and
sera were obtained from patients receiving care in the
outpatient Rheumatology clinics at the Los Angeles County
and University of Southern California Medical Center. RA
and systemic lupus erythematosus (SLE) patients were
diagnosed according to established clinical criteria [33, 34].
All patients had to have a clinical diagnosis of RA as
defined by rheumatologists at academic center. The
sampling was on consecutive RA patients from LA County
hospital who had a joint effusion that was aspirated. Due to
use of biologic agents, much less effusions are seen in the
clinic. Patient population was mostly Hispanic, approxi-
mately 80%, with active RA stage 2 to 4 with most
probably falling into 2 or 3 but data not collected so this is
speculative. Comorbidities were not examined. All samples
processed within 4 h. Control sera were obtained from
healthy volunteers at the City of Hope General Clinical
Research Center. SF samples were diluted 1:5 in PBS,
centrifuged to remove cellular debris, and stored at −80°C.
There are no viscosity issues when the SF is diluted 1:5 in
PBS. Blood samples were allowed to clot overnight at 4°C.
The next day, the blood was centrifuged and the top layer of
serum was transferred into new tubes. Serum samples were
stored at −80°C until use.
Protein Fractionation
A multiple affinity removal column (Agilent Technologies,
Wilmington, DE, USA) was used to remove six abundant
proteins (albumin, IgG, antitrypsin, IgA, transferrin, and
haptoglobin) from SF. The procedure removed 85–90% of
the total protein mass, which increased the probability of
detecting the lower abundance proteins. Depletion was
performed according to manufacturer’s protocol. After the
depletion, samples were desalted by use of a 5-kDa MWCO
spin filter (Amicon Ultra-15, Millipore Corp., Bedford,
MA, USA). Reactivity of RA sera to proteins in the 5-kDa
filtrate was not detected. Protein concentration of the
desalted SF was determined by RCDC protein assay
(BioRad Laboratories, Hercules, CA, USA).
SF proteins were separated by 2D-HPLC, chromatofo-
cusing, and reverse phase (RP) HPLC. A Beckman PF2D
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System (Beckman Coulter, Inc., Fullerton, CA, USA) with
a PF2D kit (column and buffers) was used for the first-
dimension separation. Approximately 5 mg of proteins was
separated in the pH range 8.5 to 4.0. After loading, the
sample was washed in start buffer for 20 min, eluant buffer
for 75 min, and then 1 M sodium chloride buffer for
45 min. The column was then washed overnight in water.
Fractions were collected in increments of 5 min or 0.2 pH
units, whichever came first, into a cooled deep well 96-well
plate. This separation was reproducible as performed
according to manufacturers’ supplied protocol. The
second-dimension separation was performed on a Vydac
C4 column (5 um, 300 A, 2.1×250 mm) using the
following program: hold for 12 min at 5% buffer B; 5%
to 95% buffer B in 25 min; hold at 95% buffer B for 8 min.
The flow rate was 0.25 ml/min. Fractions were collected
between 14 and 45 min at every 2 min into standard 96-
well plates using a fraction collector.
The pooled SF second-dimension separations were
performed on a Vydac C4 column (10 um, 300 A, 4.6×
250 mm) using a gradient of 2% to 98% buffer B in 60 min
and a flow rate of 1 ml/min. Corresponding fractions that
eluted in the same pH range from four first-dimension runs
were combined to ensure enough material was obtained for
analysis by mass spectrometry. Buffer A consisted of 0.1%
TFA. Buffer B consisted of 0.1% TFA in 90% acetonitrile.
A Beckman System Gold 126 equipped with a model 168
diode array detector (Beckman Coulter, Inc.) was used to
perform the separations. Fractions were collected every
minute. Samples were frozen and lyophilized to dryness.
Protein Arrays
Custom arrays were hand made using a VP 409 replicator
with 96 pins each holding 100 nl of fluid (V&P Scientific,
Inc., San Diego, CA, USA). The selected HPLC fractions
were resuspended in ∼200 μl of 6 M urea/sodium
bicarbonate pH 8.0. The microtiter plates were slowly
rocked for about 30 min to facilitate protein solubility. The
replicator was dipped into a 96-well plate, and the fluid
(∼100 nl) retained on the tips of the pins was transferred to
a nitrocellulose membrane. Each fraction was arrayed in
triplicate. To serve as a positive control for serum antibody
reactivity, an influenza vaccine preparation also was
arrayed. After drying overnight in a laminar flow hood,
the arrayed membranes were blocked overnight in a non-fat
dried milk solution and subsequently were rinsed twice in
TBS (20 mM Tris–HCl, 500 mM NaCl, pH 7.5). The arrays
were incubated with a 1:200 dilution of RA or control sera
for 1 h at room temperature. After rinsing twice in TBS, the
arrays were incubated with a 1:100,000 dilution of HRP-
conjugated F(ab′)2 goat anti-human IgG + IgM + IgA
secondary antibodies (Jackson ImmunoResearch Laborato-
ries, Inc., West Grove, PA, USA). The arrays were washed
twice with 3% newborn calf serum/0.05% Tween/TBS,
twice with a 0.05% Tween/TBS, twice with TBS, and twice
with water. ECL Plus Western Blotting Detection Reagents
(GE Healthcare, Piscataway, NJ, USA) were used as the
detection agent. The arrays were imaged on a Typhoon
9410 (GE Healthcare) using the following conditions: Laser
(457 nm), Emission filter (520BP40), Focal Plane (Platen),
Pixel Size (50 μm), Sensitivity (Normal). Different voltages
were used to scan the images but typically 500v was used
for most of the images. To distinguish background noise
from foreground signal by a statistical method that
complemented the visual inspection of the protein arrays,
the median filter smoothing technique was applied to the
imaged signals as described [35].
Mass Spectrometry
Approximately 80% of the solubilized RP-HPLC fraction
was digested with trypsin (Promega, Madison, WI, USA).
Approximately 5% of the digested material was analyzed
by LC/MS/MS. Analyses were performed on a Thermo
Finnigan LTQ-FT linear ion trap-Fourier transform mass
spectrometer (Thermo Electron Corporation, San Jose, CA,
USA) coupled to an Eksigent nanoLC-2D capillary HPLC
system (Eksigent Technologies, LLC, Dublin, CA, USA).
Samples were loaded onto a 300 μm×5 mm C18 trapping
column (Dionex Corporation, Sunnyvale, CA, USA) and
then eluted through a lab-built 75 μm×10 cm analytical
column packed with 3 μm C18 Pursuit resin (Varian, Inc.,
Palo Alto, CA, USA). The gradient for the trapping column
was 100% A for 5 min using a flow rate of 10 μl/min. The
gradient for the analytical column was 2% to 35% B in
45 min, 35% to 50% B in 4 min, and 50% to 95% B in
2 min using a flow rate of 0.2 μl/min. High-resolution full-
scale mass spectra were acquired in the Fourier transform-
ion cyclotron resonance (FT-ICR) section of the mass
spectrometer while fragment ion (MS/MS) spectra were
obtained from the linear ion trap section. Fragmentation
was performed using a collision energy setting of 35.
Dynamic exclusion was set at 15 s.
Monoisotopic peaks and peptide charge states were
determined during acquisition by the Xcalibur acquisition
software using the high-resolution Fourier transform mass
spectrometry (FTMS) spectra. Protein identifications were
made by SEQUEST [36]. SEQUEST searches were
performed with the following parameters: use of the 10/
17/08 release of the SwissProt database (downloaded from
ftp://ftp.ncbi.nlm.nih.gov/blast/db), monoisotopic masses,
partial trypsin cleavage, 2 amu peptide and fragment
tolerance, and automatic charge state determination. The
SwissProt database was filtered to include only entries
containing _HUMAN as a parameter. Peptide hits were
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filtered using the following criteria: DeltaCn greater than
or equal to 0.08, XC greater than or equal to 1.8 for
peptides having +1 charge, 2.5 for peptides with a +2
charge, and 3.5 for peptides having a +3 charge and the
peptide must be to a protein with probability score less
than 0.0001 used [37]. Peptides meeting these criteria
were further analyzed. Although the LTQ-FT has routine
mass accuracy of 2 ppm, it is set to perform MS/MS on
the most abundant peak in an isotope envelope, rather than
the monoisotopic mass. This frequency results in errors of
1 or 2 mass units for large peptides. Because SEQUEST
and extract_msn do not correct for this error, it was
necessary to set peptide mass tolerance to 2.5 to account
for errors in precursor assignment. Fragment ion tolerance
was set at 0.0. The searches were performed assuming
both trypsin and no enzyme specificity. Spectra were hand
sorted to identify and verify post-translational modifica-
tions (PTM). All charge states and mass were manually
verified using the high-resolution FTMS data. All spectra
corresponding to candidate autoantigens were manually
verified.
Synthetic Peptides
The FIBA 259–287 peptides with and without the citrulline
substitution for arginine 271 (MELERPGGNEITR*GGST-
SYGTGSETESPR) were synthesized in the City of Hope
Peptide Synthesis Core Facility. The synthesized profilag-
grin 619–631 peptide (SSFSQDR*DSQAQS) contained a
citrulline for arginine substitution at position 625. Peptides
were dissolved in 0.1% TFA and purified two to three times
on a C18 reverse phase column. Concentration was
determined by amino acid analysis.
ELISA
Maleic anhydride coated ELISA plates (Pierce Biotechnol-
ogy, Inc., Rockford, IL, USA) were incubated overnight
with 100 μl of 12.5 μg/ml peptide in PBS. The plates were
blocked overnight in a dried milk solution, washed twice in
TBS, and incubated overnight in a 1:20 dilution of patient
sera. After rinsing two times in TBS, the plates were
incubated in a 1:10,000 dilution of HRP-conjugated F(ab′)2
goat anti-human IgG + IgM + IgA secondary antibodies for
1 h. The plates were then rinsed 6 times in TBS. For color
development 150 μl ABTS (Pierce Biotechnology) was
Synovial Fluid 
(late RA, early RA, serum from healthy control) 
 
Abundant Protein Depletion 
(Agilent Column, flowthru from 15 runs) 
 
1D-HPLC, Chromatofocusing  
(Approx. 40 fractions collected into deep well plates) 
 
2D-HPLC, Reverse Phase 
(Approx 1280 fractions collected into standard 96-well plates)
 
Macroarrays  
(Screen Fractions with RA Serum to detect Presence of Autoantigens)
 
Identify Autoantigens by Mass Spectrometry 
 
Identify Post-translationally Modified Sites 
 
Verify Peptide Epitope Reactivity with RA sera by ELISA 
Fig. 1 Proteomic Strategy to Identify autoantigens present in synovial
fluid of RA patients
Fig. 2 Fraction containing can-
didate autoantigen detected on
second-dimension RP-HPLC.
Fractions from the SF separation
were spotted in a protein array,
which was used to determine
which fractions contained an
autoantigen. Arrow points pa-
tient synovial fluid fraction that
reacted with RA patient serum
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added to the wells and incubated for 30 min. To stop the
reaction, 100 μl of 1% SDS was added. The absorbance at
405 nm was read on a plate reader.
Results
A targeted proteomic approach was performed to identify
autoantigens in RA SF. The experimental design is
diagrammed in Fig. 1. An immunodepletion column was
first used to remove six abundant serum proteins (albumin,
antitrypsin, haptoglobin, IgA, IgG, and transferrin). The
depleted SF was then fractionated by chromatofocusing
HPLC (provided as Supplement Fig. 1) and reverse phase
HPLC (provided as Supplement Fig. 2). This protein
fractionation strategy increased the chance of identifying
the lower abundance proteins by separating them from the
higher abundance proteins. The second-dimension fractions
were used to construct protein arrays on nitrocellulose
membranes, which were used to test for the presence of
autoantigens by analyzing differential reactivity of RA and
control sera. We focused on one second-dimension fraction
resulting from the separation of the first-dimension fraction
eluting at pH 5.63–5.45 (Fig. 2) that tested positive when
probed with RA serum but negative when probed with
normal control serum. This was the only fraction that tested
positive in which a peak was detected on the HPLC
chromatographs. Although there was sufficient material for
Fig. 3 a Representative HPLC
chromatogram for the first-
dimension chromatofocusing
separation of the abundant pro-
tein depleted SF sample. The
diagonal line indicates the ob-
served pH gradient. The frac-
tions corresponding to the
elution range of pH 5.63–5.45
from four runs were combined
for the second-dimension sepa-
ration. b HPLC chromatogram
for the second-dimension re-
verse phase separation. This
sample was separated on a
Beckman System Gold HPLC
coupled to a diode array detec-
tor. The diagonal line indicates
the solvent gradient (%B). The
fraction (between 20 and
25 min) corresponding to the
region that tested positive in the
protein array assay was selected
for further characterization by
mass spectrometry
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Table 1 Proteins identified in the B2 second-dimension RP fractions
P (pro) Score MW Hits
Fraction 13 proteins
K1C9_HUMAN Keratin, type I cytoskeletal 9 3.93E−13 60.40 62,091.8 6
PRG4_HUMAN Proteoglycan-4 5.32E−13 40.33 15,0,983.2 5
GRP78_HUMAN 78 kDa glucose-regulated protein 1.57E−09 10.25 72,288.5 1
ALBU_HUMAN Serum albumin 2.20E−09 40.24 69,321.6 5
TYB4_HUMAN Thymosin beta-4 1.25E−07 30.23 5,049.5 6
K2C1_HUMAN Keratin, type II cytoskeletal 1 2.44E−07 96.26 65,977.9 10
K1C10_HUMAN Keratin, type I cytoskeletal 10 2.80E−07 30.25 59,474.8 3
Fraction 14 proteins
K1C9_HUMAN Keratin, type I cytoskeletal 9 1.00E−30 110.27 62,091.8 13
PRG4_HUMAN Proteoglycan-4 1.22E−14 60.34 150,983.2 11
K2C6C_HUMAN Keratin, type II cytoskeletal 6C 1.33E−14 10.31 59,988.4 2
K2C1_HUMAN Keratin, type II cytoskeletal 1 2.93E−11 126.39 65,977.9 15
K1C10_HUMAN Keratin, type I cytoskeletal 10 7.90E−10 10.26 59,474.8 1
ALBU_HUMAN Serum albumin 2.28E−09 10.22 69,321.6 2
TTHY_HUMAN Transthyretin 3.41E−08 20.26 15,877.1 4
BASP_HUMAN Brain acid soluble protein 1 5.02E−07 20.25 22,680.0 2
EFHD2_HUMAN EF-hand domain-containing protein D2 1.42E−06 10.19 26,680.5 1
K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal 1.16E−05 10.21 65,825.4 1
APOA2_HUMAN Apolipoprotein A-II 3.90E−04 10.15 11,167.9 1
Fraction 15 proteins
PRG4_HUMAN Proteoglycan-4 1.13E−11 50.33 150,983.2 8
K1C10_HUMAN Keratin, type I cytoskeletal 10 3.63E−10 30.27 59,474.8 3
K1C9_HUMAN Keratin, type I cytoskeletal 9 9.80E−08 30.41 62,091.8 3
FIBA_HUMAN Fibrinogen alpha chain 7.51E−07 30.22 94,914.3 6
K2C1_HUMAN Keratin, type II cytoskeletal 1 6.51E−06 70.26 65,977.9 7
PMS2_HUMAN Mismatch repair endonuclease PMS2 2.41E−05 10.19 95,737.1 1
APOA1_HUMAN Apolipoprotein A-I 3.14E−05 30.13 30,758.9 7
K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal 1.45E−04 10.20 65,825.4 1
S10A6_HUMAN Protein S100-A6 4.94E−04 10.13 10,173.3 1
Fraction 20 proteins
K2C6C_HUMAN Keratin, type II cytoskeletal 6C 3.02E−12 20.30 59,988.4 3
FIBA_HUMAN Fibrinogen alpha chain 4.08E−12 408.35 94,914.3 87
K2C1_HUMAN Keratin, type II cytoskeletal 1 2.09E−11 106.30 65,977.9 12
APOA4_HUMAN Apolipoprotein A-IV 4.79E−11 20.25 45,371.5 3
K1C10_HUMAN Keratin, type I cytoskeletal 10 1.88E−10 30.23 59,474.8 3
K1C9_HUMAN Keratin, type I cytoskeletal 9 4.42E−10 60.31 62,091.8 6
ALBU_HUMAN Serum albumin 5.87E−08 20.21 69,321.6 3
OSTP_HUMAN Osteopontin 7.36E−07 10.22 35,401.3 1
APOA1_HUMAN Apolipoprotein A-I 1.23E−05 20.20 30,758.9 2
K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal 6.83E−05 10.22 65,825.4 1
Fraction 21 proteins
K1C9_HUMAN Keratin, type I cytoskeletal 9 1.00E−30 70.31 62,091.8 8
K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal 5.55E−15 30.28 65,825.4 4
K2C6C_HUMAN Keratin, type II cytoskeletal 6C 1.11E−14 10.29 59,988.4 2
K2C1_HUMAN Keratin, type II cytoskeletal 1 6.48E−13 100.38 65,977.9 12
FIBA_HUMAN Fibrinogen alpha chain 8.06E−12 428.33 94,914.3 87
OSTP_HUMAN Osteopontin 2.97E−09 70.25 35,401.3 14
K1C10_HUMAN Keratin, type I cytoskeletal 10 8.09E−09 40.24 59,474.8 4
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Table 1 (continued)
P (pro) Score MW Hits
ADIPO_HUMAN Adiponectin 2.01E−08 10.22 26,397.0 2
APOA1_HUMAN Apolipoprotein A-I 3.54E−08 110.20 30,758.9 15
K2C5_HUMAN Keratin, type II cytoskeletal 5 4.79E−08 10.25 62,340.0 1
HEP2_HUMAN Heparin cofactor 2 1.86E−07 20.26 57,034.3 6
A2MG_HUMAN Alpha-2-macroglobulin 4.97E−07 10.22 163,174.3 2
HPT_HUMAN Haptoglobin 2.91E−06 62.22 45,176.6 11
APOB_HUMAN Apolipoprotein B-100 1.20E−05 10.17 515,241.6 2
APOA4_HUMAN Apolipoprotein A-IV 1.46E−05 20.19 45,371.5 2
CLUS_HUMAN Clusterin 5.35E−05 10.16 52,461.1 1
K2C75_HUMAN Keratin, type II cytoskeletal 75 1.47E−04 16.20 59,468.0 2
CD99_HUMAN CD99 antigen 1.73E−04 10.16 18,836.3 1
Fraction 22 proteins
K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal 1.00E−30 130.30 65,825.4 17
K1C9_HUMAN Keratin, type I cytoskeletal 9 6.66E−15 80.38 62,091.8 9
K2C1_HUMAN Keratin, type II cytoskeletal 1 5.66E−14 226.35 65,977.9 34
HPT_HUMAN Haptoglobin 1.12E−13 98.26 45,176.6 25
FIBA_HUMAN Fibrinogen alpha chain 1.22E−11 588.31 94,914.3 115
K1C10_HUMAN Keratin, type I cytoskeletal 10 2.69E−11 200.34 59,474.8 34
K2C6C_HUMAN Keratin, type II cytoskeletal 6C 4.30E−11 50.31 59,988.4 7
FETUA_HUMAN Alpha-2-HS-glycoprotein 2.71E−09 10.21 39,299.7 1
PLMN_HUMAN Plasminogen 3.35E−09 20.28 90,510.2 5
K2C5_HUMAN Keratin, type II cytoskeletal 5 7.18E−08 20.22 62,340.0 3
K1C14_HUMAN Keratin, type I cytoskeletal 14 9.30E−08 20.17 51,589.5 2
APOA1_HUMAN Apolipoprotein A-I 1.80E−07 158.21 30,758.9 78
LBR_HUMAN Lamin-B receptor 7.18E−07 10.18 70,658.2 1
UPAR_HUMAN Urokinase plasminogen activator surface receptor 8.12E−07 10.24 36,953.3 1
FINC_HUMAN Fibronectin 8.99E−07 30.22 262,439.5 4
ECM1_HUMAN Extracellular matrix protein 1 1.83E−06 20.18 60,635.4 2
K2C6A_HUMAN Keratin, type II cytoskeletal 6A 1.85E−06 10.13 60,008.3 1
TMOD3_HUMAN Tropomodulin-3 2.02E−06 10.20 39,570.3 1
K1C24_HUMAN Keratin, type I cytoskeletal 24 3.28E−06 10.16 55,053.5 1
OSTP_HUMAN Osteopontin 9.62E−06 30.24 35,401.3 6
K1C17_HUMAN Keratin, type I cytoskeletal 17 1.05E−05 30.17 48,076.1 3
APOB_HUMAN Apolipoprotein B-100 2.09E−05 10.15 515,241.6 1
K2C75_HUMAN Keratin, type II cytoskeletal 75 2.46E−05 36.21 59,468.0 4
CFAB_HUMAN Complement factor B 2.82E−05 40.22 85,478.6 6
DEF3_HUMAN Neutrophil defensin 3 6.01E−05 10.14 10,238.2 2
HEP2_HUMAN Heparin cofactor 2 2.17E−04 10.25 57,034.3 1
Fraction 23 proteins
K2C6C_HUMAN Keratin, type II cytoskeletal 6C 1.55E−14 10.35 59,988.4 3
FIBA_HUMAN Fibrinogen alpha chain 2.36E−11 180.27 94,914.3 23
K2C1_HUMAN Keratin, type II cytoskeletal 1 4.97E−11 110.35 65,977.9 12
IBP6_HUMAN Insulin-like growth factor-binding protein 6 6.63E−11 20.26 25,306.2 3
K2C5_HUMAN Keratin, type II cytoskeletal 5 2.42E−10 10.31 62,340.0 1
K1C9_HUMAN Keratin, type I cytoskeletal 9 2.71E−10 110.33 62,091.8 12
K1C10_HUMAN Keratin, type I cytoskeletal 10 2.05E−09 50.30 59,474.8 5
APOA1_HUMAN Apolipoprotein A-I 7.38E−08 100.23 30,758.9 31
TTHY_HUMAN Transthyretin 1.41E−07 40.28 15,877.1 8
APOC3_HUMAN Apolipoprotein C-III 7.99E−07 10.25 10,845.5 1
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Table 1 (continued)
P (pro) Score MW Hits
CLUS_HUMAN Clusterin 9.57E−07 30.20 52,461.1 5
K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal 1.13E−06 10.21 65,825.4 1
CFAB_HUMAN Complement factor B 1.29E−06 60.23 85,478.6 10
PLMN_HUMAN Plasminogen 1.69E−06 10.25 90,510.2 1
K2C75_HUMAN Keratin, type II cytoskeletal 75 1.01E−04 16.21 59,468.0 2
ACTS_HUMAN Actin, alpha skeletal muscle 1.21E−04 10.15 42,023.9 1
STP2_HUMAN Nuclear transition protein 2 5.46E−04 10.19 15,630.8 1
Fraction 24 proteins
K2C6C_HUMAN Keratin, type II cytoskeletal 6C 1.00E−30 10.33 59,988.4 2
K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal 2.22E−15 40.25 65,825.4 4
K2C1_HUMAN Keratin, type II cytoskeletal 1 8.66E−14 170.28 65,977.9 18
K1C9_HUMAN Keratin, type I cytoskeletal 9 5.47E−12 80.34 62,091.8 9
FIBA_HUMAN Fibrinogen alpha chain 4.36E−10 410.31 94,914.3 93
IBP6_HUMAN Insulin-like growth factor-binding protein 6 1.62E−09 10.24 25,306.2 2
APOC3_HUMAN Apolipoprotein C-III 2.04E−09 20.27 10,845.5 4
FHR4_HUMAN Complement factor H-related protein 4 2.82E−09 20.28 37,300.4 10
FINC_HUMAN Fibronectin 7.99E−09 110.25 262,439.5 15
CO3_HUMAN Complement C3 1.44E−08 30.23 187,029.3 3
KNG1_HUMAN Kininogen-1 1.81E−08 10.21 71,912.1 3
AHNK_HUMAN Neuroblast differentiation-associated protein AHNAK 2.21E−08 144.21 628,705.2 17
CFAI_HUMAN Complement factor I 3.09E−08 10.22 65,676.7 1
TTHY_HUMAN Transthyretin 3.45E−08 70.27 15,877.1 13
PLMN_HUMAN Plasminogen 6.87E−08 20.26 90,510.2 3
CLUS_HUMAN Clusterin 1.57E−07 10.21 52,461.1 1
EMIL2_HUMAN EMILIN-2 1.82E−07 10.23 115,544.0 1
UPAR_HUMAN Urokinase plasminogen activator surface receptor 2.83E−07 10.25 36,953.3 1
APOA1_HUMAN Apolipoprotein A-I 6.53E−07 100.23 30,758.9 23
PRIO_HUMAN Major prion protein 7.31E−07 10.21 27,643.2 2
HRG_HUMAN Histidine-rich glycoprotein 1.84E−06 10.19 59,540.9 1
FHR1_HUMAN Complement factor H-related protein 1 2.60E−06 30.17 37,637.0 3
CFAB_HUMAN Complement factor B 3.71E−06 80.21 85,478.6 10
HPT_HUMAN Haptoglobin 6.41E−06 38.18 45,176.6 7
FHR3_HUMAN Complement factor H-related protein 3 9.61E−06 20.16 37,298.8 2
K1C10_HUMAN Keratin, type I cytoskeletal 10 1.00E−05 20.19 59,474.8 2
RETBP_PANTR Plasma retinol-binding protein 1.19E−05 30.18 22,995.3 4
GDIS_HUMAN Rho GDP-dissociation inhibitor 2 1.48E−05 20.22 22,973.6 2
NHERF_HUMAN Ezrin–radixin–moesin-binding phosphoprotein 50 4.74E−05 20.16 38,844.6 2
IBP3_HUMAN Insulin-like growth factor-binding protein 3 9.03E−05 40.18 31,653.8 7
ACTS_HUMAN Actin, alpha skeletal muscle 2.25E−04 10.15 42,023.9 1
K2C75_HUMAN Keratin, type II cytoskeletal 75 2.54E−04 16.21 59,468.0 2
HSPB1_HUMAN Heat shock protein beta-1 3.19E−04 10.15 22,768.5 1
APOC2_HUMAN Apolipoprotein C-II 4.13E−04 10.16 11,276.8 1
ADAM8_HUMAN ADAM 8 5.40E−04 10.15 88,615.7 1
Fraction 30 proteins
HEMO_HUMAN Hemopexin 5.65E−16 604.31 51,643.3 307
CFAI_HUMAN Complement factor I 1.11E−15 300.33 65,676.7 79
FETUB_HUMAN Fetuin-B 3.33E−15 80.26 42,028.0 14
AMBP_HUMAN AMBP protein 2.00E−14 20.24 38,974.0 2
IGKC_HUMAN Ig kappa chain C region 7.99E−14 30.27 11,601.7 11
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Table 1 (continued)
P (pro) Score MW Hits
TTHY_HUMAN Transthyretin 1.11E−13 150.29 15,877.1 44
TRFE_HUMAN Serotransferrin 2.02E−13 40.33 76,999.7 4
RETBP_PANTR Plasma retinol-binding protein 4.00E−13 70.32 22,995.3 33
VTDB_HUMAN Vitamin D-binding protein 9.50E−13 20.27 52,929.1 3
CO7_HUMAN Complement component C7 3.29E−12 80.22 93,457.3 10
FIBG_HUMAN Fibrinogen gamma chain 1.25E−11 120.29 51,478.9 27
FIBA_HUMAN Fibrinogen alpha chain 1.75E−11 70.28 94,914.3 8
ITIH4_HUMAN Inter-alpha-trypsin inhibitor heavy chain H4 2.39E−11 80.29 103,261.2 22
ALBU_HUMAN Serum albumin 4.44E−11 716.29 69,321.6 473
APOC3_HUMAN Apolipoprotein C-III 1.08E−10 38.26 10,845.5 6
FIBB_HUMAN Fibrinogen beta chain 2.14E−10 130.29 55,892.2 25
TENX_HUMAN Tenascin-X 7.70E−10 10.21 464,165.9 1
A2MG_HUMAN Alpha-2-macroglobulin 2.49E−09 10.17 163,174.3 1
HBB_HUMAN Hemoglobin subunit beta 6.11E−09 28.22 15,988.3 3
FETUA_HUMAN Alpha-2-HS-glycoprotein 1.00E−08 20.26 39,299.7 2
APOA1_HUMAN Apolipoprotein A-I 2.09E−08 110.23 30,758.9 34
HPTR_HUMAN Haptoglobin-related protein 3.73E−08 10.18 38,982.7 1
K2C1_HUMAN Keratin, type II cytoskeletal 1 4.44E−08 10.34 65,977.9 2
CERU_HUMAN Ceruloplasmin 4.89E−08 10.22 122,127.6 1
HBA_HUMAN Hemoglobin subunit alpha 6.40E−08 10.23 15,247.9 3
PCOC1_HUMAN Procollagen C-endopeptidase enhancer 1 2.70E−07 30.16 47,942.0 7
CO3A1_HUMAN Collagen alpha-1(III) chain 4.23E−07 20.21 138,479.2 2
LAC_HUMAN Ig lambda chain C regions 5.62E−07 20.23 11,229.5 9
HPT_HUMAN Haptoglobin 7.82E−07 38.18 45,176.6 13
CATB_HUMAN Cathepsin B 1.21E−06 20.21 37,796.8 2
MUCB_HUMAN Ig mu heavy chain disease protein 1.89E−06 38.19 43,030.3 4
IGHA2_HUMAN Ig alpha-2 chain C region 4.73E−06 10.13 36,485.1 2
COR1A_HUMAN Coronin-1A 6.19E−06 10.23 50,993.9 1
TETN_HUMAN Tetranectin 9.66E−06 30.24 22,552.3 5
IGHM_HUMAN Ig mu chain C region 1.93E−05 20.26 49,275.6 3
CFAB_HUMAN Complement factor B 2.98E−05 40.18 85,478.6 4
CAPG_HUMAN Macrophage-capping protein 3.70E−05 40.20 38,493.6 6
IGHD_HUMAN Ig delta chain C region 4.73E−05 10.14 42,227.3 1
IGHA1_HUMAN Ig alpha-1 chain C region 1.52E−04 10.18 37,630.7 1
ATS9_HUMAN ADAMTS-9 4.44E−04 10.15 216,415.5 1
Fraction 31 proteins
CFAB_HUMAN Complement factor B 1.00E−30 296.35 85,478.6 74
CO8A_HUMAN Complement component C8 alpha chain 1.00E−30 104.27 65,121.0 18
TTHY_HUMAN Transthyretin 1.11E−16 340.32 15,877.1 103
CERU_HUMAN Ceruloplasmin 1.11E−16 80.31 122,127.6 10
RETBP_PANTR Plasma retinol-binding protein 1.11E−16 70.31 22,995.3 31
HEMO_HUMAN Hemopexin 2.22E−16 236.31 51,643.3 85
K1C9_HUMAN Keratin, type I cytoskeletal 9 4.44E−16 20.39 62,091.8 2
HBA_HUMAN Hemoglobin subunit alpha 4.44E−15 40.29 15,247.9 5
S10AC_HUMAN Protein S100-A12 6.66E−15 10.30 10,568.5 1
CO8G_HUMAN Complement component C8 gamma chain 7.77E−15 60.26 22,263.6 11
IGKC_HUMAN Ig kappa chain C region 9.99E−15 70.30 11,601.7 53
ITIH4_HUMAN Inter-alpha-trypsin inhibitor heavy chain H4 1.44E−14 468.31 103,261.2 188
IGHA1_HUMAN Ig alpha-1 chain C region 5.46E−12 80.32 37,630.7 35
Clin Proteom (2009) 5:75–102 83
Table 1 (continued)
P (pro) Score MW Hits
APOC2_HUMAN Apolipoprotein C-II 5.67E−12 60.28 11,276.8 14
FIBB_HUMAN Fibrinogen beta 7.98E−12 210.39 55,892.2 78
AMBP_HUMAN AMBP protein 8.25E−12 40.25 38,974.0 5
CLUS_HUMAN Clusterin 1.08E−11 148.28 52,461.1 26
HV3P_HUMAN Ig heavy chain V-III region TEI 1.38E−11 10.28 12,794.4 4
ALBU_HUMAN Serum albumin 1.48E−11 370.28 69,321.6 160
FIBG_HUMAN Fibrinogen gamma chain 1.71E−11 240.30 51,478.9 46
KV1D_HUMAN Ig kappa chain V-I region CAR 2.53E−11 10.26 11,696.3 3
AACT_HUMAN Alpha-1-antichymotrypsin 3.63E−11 10.21 47,620.6 1
LAC_HUMAN Ig lambda chain C regions 5.29E−11 60.26 11,229.5 16
IGHA2_HUMAN Ig alpha-2 chain C region 5.55E−11 120.26 36,485.1 44
HPT_HUMAN Haptoglobin 8.17E−11 110.29 45,176.6 25
ENOB_HUMAN Beta-enolase 1.28E−10 10.24 46,957.4 1
ENOA_HUMAN Alpha-enolase 1.31E−10 30.26 47,139.4 3
APOA1_HUMAN Apolipoprotein A-I 1.45E−10 330.30 30,758.9 111
CFAI_HUMAN Complement factor I 1.53E−10 118.28 65,676.7 23
COR1A_HUMAN Coronin-1A 1.97E−10 64.25 50,993.9 8
HBD_HUMAN Hemoglobin subunit delta 2.66E−10 78.23 16,045.3 12
FETUA_HUMAN Alpha-2-HS-glycoprotein 6.50E−10 20.27 39,299.7 4
DIAC_HUMAN Di-N-acetylchitobiase 9.02E−10 20.20 43,731.6 2
A2AP_HUMAN Alpha-2-antiplasmin 9.62E−10 40.24 54,531.2 4
KV3H_HUMAN Ig kappa chain V-III region CLL 1.61E−09 18.23 14,266.2 4
SHBG_HUMAN Sex hormone-binding globulin 2.19E−09 60.24 43,751.9 6
ENO1B_HUMAN Alpha-enolase, lung specific 2.99E−09 10.21 49,446.4 2
AIF1_HUMAN Allograft inflammatory factor 1 3.56E−09 10.23 16,692.6 1
FRIH_HUMAN Ferritin heavy chain 5.57E−09 60.25 21,212.3 8
FIBA_HUMAN Fibrinogen alpha chain 7.21E−09 98.28 94,914.3 17
IGHD_HUMAN Ig delta chain C region 7.77E−09 30.23 42,227.3 6
LUM_HUMAN Lumican 1.22E−08 60.30 38,404.8 14
GELS_HUMAN Gelsolin 2.34E−08 20.21 85,644.3 2
HBB_HUMAN Hemoglobin subunit beta 2.70E−08 50.22 15,988.3 14
COF1_HUMAN Cofilin-1 3.91E−08 10.26 18,490.7 1
KV1S_HUMAN Ig kappa chain V-I region Wes 4.88E−08 10.21 11,600.7 1
MUCB_HUMAN Ig mu heavy chain disease protein 5.93E−08 56.22 43,030.3 15
LV3B_HUMAN Ig lambda chain V-III region LOI 9.13E−08 20.24 11,927.8 6
FETUB_HUMAN Fetuin-B 9.28E−08 60.27 42,028.0 8
K2C1_HUMAN Keratin, type II cytoskeletal 1 1.53E−07 46.37 65,977.9 6
IGHM_HUMAN Ig mu chain C region 2.18E−07 30.23 49,275.6 5
MMP1_HUMAN Interstitial collagenase 2.78E−07 30.21 53,972.8 3
COTL1_HUMAN Coactosin-like protein 3.14E−07 10.23 15,935.0 1
KV3G_HUMAN Ig kappa chain V–III region GOL 3.86E−07 10.21 11,823.0 4
CATB_HUMAN Cathepsin B 3.96E−07 10.16 37,796.8 1
S10A9_HUMAN Protein S100-A9 4.68E−07 10.19 13,233.5 1
THIO_HUMAN Thioredoxin 4.91E−07 10.18 11,729.7 4
TRFE_HUMAN Serotransferrin 5.57E−07 50.26 136,191 6
A2MG_HUMAN Alpha-2-macroglobulin 6.03E−07 20.21 163,174.3 3
ANT3_HUMAN Antithrombin-III 6.29E−07 10.21 52,569.0 1
KPYM_HUMAN Pyruvate kinase isozymes M1/M2 7.06E−07 10.24 57,900.2 1
PROF1_HUMAN Profilin-1 (Profilin I) 8.10E−07 30.20 15,044.6 3
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P (pro) Score MW Hits
CO8B_HUMAN Complement component C8 beta chain 8.76E−07 30.17 67,003.5 3
PCOC1_HUMAN Procollagen C-endopeptidase enhancer 1 1.74E−06 20.19 47,942.0 2
HV3J_HUMAN Ig heavy chain V-III region HIL 1.97E−06 10.19 13,557.2 3
SAMP_HUMAN Serum amyloid P-component 2.29E−06 10.16 25,371.1 1
KV3I_HUMAN Ig kappa chain V–III region VG 2.90E−06 20.25 12,567.3 4
CAPG_HUMAN Macrophage-capping protein 3.08E−06 10.20 38,493.6 1
APOC3_HUMAN Apolipoprotein C-III 4.71E−06 20.21 10,845.5 3
CO7_HUMAN Complement component C7 5.24E−06 48.24 93,457.3 6
ADIPO_HUMAN Adiponectin 7.98E−06 10.22 26,397.0 1
KV1V_HUMAN Ig kappa chain V-I region BAN 9.70E−06 10.21 11,832.8 1
HV1G_HUMAN Ig heavy chain V-I region V35 1.01E−05 10.15 13,000.4 1
KV4C_HUMAN Ig kappa chain V-IV region B17 2.11E−05 20.16 14,956.5 2
TETN_HUMAN Tetranectin 2.36E−05 10.18 22,552.3 1
APOD_HUMAN Apolipoprotein D 7.83E−05 20.13 21,261.8 4
IGLL1_HUMAN Immunoglobulin lambda-like polypeptide 1 8.60E−05 28.19 22,948.6 3
IGJ_HUMAN Immunoglobulin J chain 8.94E−05 10.13 15,584.6 1
HV3R_HUMAN Ig heavy chain V-III region TUR 1.01E−04 10.22 12,423.3 3
SAA4_HUMAN Serum amyloid A-4 protein 1.78E−04 10.16 14,797.3 2
HV1C_HUMAN Ig heavy chain V-I region ND 1.93E−04 10.13 16,493.0 1
HPTR_HUMAN Haptoglobin-related protein 1.94E−04 10.18 38,982.7 1
LV3A_HUMAN Ig lambda chain V-III region SH 5.30E−04 10.17 11,385.6 2
CO1A1_HUMAN Collagen alpha-1(I) chain 5.86E−04 10.15 138,826.8 1
MBOA2_HUMAN Membrane-bound O-acyltransferase domain-containing 7.03E−04 10.11 59,488.3 1
ZA2G_HUMAN Zinc-alpha-2-glycoprotein 8.67E−04 10.14 33,850.9 1
Fraction 32 proteins
TTHY_HUMAN Transthyretin 1.00E−30 350.34 15,877.1 114
HBA_HUMAN Hemoglobin subunit alpha 1.00E−30 90.31 15,247.9 15
CO8B_HUMAN Complement component C8 beta chain 1.00E−30 10.26 67,003.5 1
CFAB_HUMAN Complement factor B 7.77E−15 220.34 85,478.6 52
ITIH2_HUMAN Inter-alpha-trypsin inhibitor heavy chain H2 8.88E−15 10.29 106,369.8 1
CO8G_HUMAN Complement component C8 gamma chain 9.99E−15 30.25 22,263.6 5
K1C9_HUMAN Keratin, type I cytoskeletal 9 9.99E−15 20.38 62,091.8 2
CERU_HUMAN Ceruloplasmin 1.11E−14 60.28 122,127.6 7
CLUS_HUMAN Clusterin 1.67E−14 190.29 52,461.1 57
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase 2.11E−14 50.33 36,030.4 5
CBPN_HUMAN Carboxypeptidase N catalytic chain 3.55E−14 20.26 52,253.4 3
RETBP_PANTR Plasma retinol-binding protein 4.00E−14 60.32 22,995.3 34
AMBP_HUMAN AMBP protein 4.00E−14 30.27 38,974.0 4
ENOA_HUMAN Alpha-enolase 5.33E−14 148.35 47,139.4 43
IGKC_HUMAN Ig kappa chain C region 5.77E−14 60.29 11,601.7 66
HEMO_HUMAN Hemopexin 2.15E−13 136.31 51,643.3 41
ANT3_HUMAN Antithrombin-III 7.48E−13 316.31 52,569.0 59
S10AC_HUMAN Protein S100-A12 1.80E−12 40.36 10,568.5 8
HBD_HUMAN Hemoglobin subunit delta 2.46E−12 206.30 16,045.3 77
KLKB1_HUMAN Plasma kallikrein 2.60E−12 50.24 71,322.8 6
ENOB_HUMAN Beta-enolase 2.71E−12 38.26 46,957.4 9
SHBG_HUMAN Sex hormone-binding globulin 5.08E−12 90.29 43,751.9 23
ITIH4_HUMAN Inter-alpha-trypsin inhibitor heavy chain H4 6.78E−12 110.29 103,261.2 25
S10A8_HUMAN Protein S100-A8 7.06E−12 20.31 10,827.7 5
Clin Proteom (2009) 5:75–102 85
Table 1 (continued)
P (pro) Score MW Hits
APOC2_HUMAN Apolipoprotein C-II 9.10E−12 100.29 11,276.8 30
PGRP2_HUMAN N-acetylmuramoyl-L-alanine amidase 1.26E−11 60.29 62,178.0 8
KV1D_HUMAN Ig kappa chain V-I region CAR 1.76E−11 10.25 11,696.3 3
KV1S_HUMAN Ig kappa chain V-I region Wes 2.20E−11 10.23 11,600.7 2
APOM_HUMAN Apolipoprotein M 2.21E−11 70.25 21,239.4 11
HBB_HUMAN Hemoglobin subunit beta 2.64E−11 208.31 15,988.3 131
IGHA1_HUMAN Ig alpha-1 chain C region 3.97E−11 80.26 37,630.7 29
LAC_HUMAN Ig lambda chain C regions 6.32E−11 60.27 11,229.5 19
CFAI_HUMAN Complement factor I 6.39E−11 116.28 65,676.7 21
KV4C_HUMAN Ig kappa chain V-IV region B17 7.16E−11 20.26 14,956.5 3
THRB_HUMAN Prothrombin 1.36E−10 40.28 69,992.2 5
APOA1_HUMAN Apolipoprotein A-I 1.44E−10 530.26 30,758.9 302
CFAD_HUMAN Complement factor D 2.12E−10 30.22 27,015.9 4
IGHA2_HUMAN Ig alpha-2 chain C region 2.79E−10 118.23 36,485.1 36
FIBB_HUMAN Fibrinogen beta chain 2.86E−10 100.27 55,892.2 16
HPT_HUMAN Haptoglobin 3.59E−10 130.32 45,176.6 28
SAMP_HUMAN Serum amyloid P-component 4.06E−10 60.21 25,371.1 12
KV3H_HUMAN Ig kappa chain V-III region CLL 5.94E−10 10.22 14,266.2 2
APOA2_HUMAN Apolipoprotein A-II 7.84E−10 60.31 11,167.9 7
HSP71_PONAB Heat shock 70 kDa protein 1 8.30E−10 10.24 70,009.2 1
CO8A_HUMAN Complement component C8 alpha chain 9.20E−10 20.25 65,121.0 2
S10A9_HUMAN Protein S100-A9 1.43E−09 40.25 13,233.5 7
ALBU_HUMAN Serum albumin 2.15E−09 262.26 69,321.6 70
VASP_HUMAN Vasodilator-stimulated phosphoprotein 2.32E−09 10.23 39,805.1 1
K2C1_HUMAN Keratin, type II cytoskeletal 1 2.40E−09 26.41 65,977.9 4
FIBA_HUMAN Fibrinogen alpha chain 2.63E−09 30.23 94,914.3 3
ADIPO_HUMAN Adiponectin 3.36E−09 10.22 26,397.0 1
FIBG_HUMAN Fibrinogen gamma chain 1.33E−08 70.27 51,478.9 14
ENO1B_HUMAN Alpha-enolase, lung specific 1.53E−08 50.29 49,446.4 9
LV4C_HUMAN Ig lambda chain V-IV region Hil 1.59E−08 10.25 11,509.6 2
IGHG3_HUMAN Ig gamma-3 chain C region 2.06E−08 10.18 41,260.4 1
COR1A_HUMAN Coronin-1A 2.58E−08 10.24 50,993.9 1
CO4A_HUMAN Complement C4-A 3.08E−08 20.24 192,649.5 2
KV3G_HUMAN Ig kappa chain V-III region GOL 3.61E−08 10.21 11,823.0 3
IGHD_HUMAN Ig delta chain C region 3.83E−08 20.19 42,227.3 3
FRIH_HUMAN Ferritin heavy chain 3.91E−08 10.21 21,212.3 1
IGHM_HUMAN Ig mu chain C region 5.37E−08 20.23 49,275.6 13
LUM_HUMAN Lumican 5.61E−08 80.26 38,404.8 17
PSA6_RAT Proteasome subunit alpha type-6 6.04E−08 20.17 27,381.8 2
MUCB_HUMAN Ig mu heavy chain disease protein 1.04E−07 58.23 43,030.3 12
LV3B_HUMAN Ig lambda chain V-III region LOI 1.17E−07 30.24 11,927.8 6
CO1A1_HUMAN Collagen alpha-1(I) chain 1.76E−07 10.15 138,826.8 1
APOE_HUMAN Apolipoprotein E 1.87E−07 20.19 36,131.8 3
CAPG_HUMAN Macrophage-capping protein 2.00E−07 10.19 38,493.6 1
LMNA_HUMAN Lamin-A/C 2.15E−07 30.20 74,094.8 4
A2MG_HUMAN Alpha-2-macroglobulin 3.81E−07 60.19 163,174.3 7
IGLL1_HUMAN Immunoglobulin lambda-like polypeptide 1 4.24E−07 38.22 22,948.6 5
CFAH_HUMAN Complement factor H 6.11E−07 10.14 139,004.4 1
GELS_HUMAN Gelsolin 1.31E−06 20.23 85,644.3 2
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HV1G_HUMAN Ig heavy chain V-I region V35 1.50E−06 10.16 13,000.4 1
CO3_HUMAN Complement C3 1.59E−06 30.22 187,029.3 3
FETUB_HUMAN Fetuin-B 1.64E−06 10.26 42,028.0 1
UBP15_HUMAN Ubiquitin carboxyl-terminal hydrolase 15 3.10E−06 10.20 112,347.6 1
GPX3_HUMAN Glutathione peroxidase 3 3.23E−06 60.20 25,386.0 6
FETUA_HUMAN Alpha-2-HS-glycoprotein 4.85E−06 20.18 39,299.7 2
APOA4_HUMAN Apolipoprotein A-IV 5.76E−06 10.19 45,371.5 1
FGFP2_HUMAN Fibroblast growth factor-binding protein 2 1.29E−05 20.18 24,565.2 2
APOC1_HUMAN Apolipoprotein C-I 2.47E−05 10.12 9,326.1 1
APOD_HUMAN Apolipoprotein D 2.86E−05 10.12 21,261.8 1
HV3P_HUMAN Ig heavy chain V-III region TEI 2.88E−05 10.20 12,794.4 3
GDIS_HUMAN Rho GDP-dissociation inhibitor 2 3.11E−05 10.18 22,973.6 1
TENA_HUMAN Tenascin 3.65E−05 10.16 240,710.7 1
HV1B_HUMAN Ig heavy chain V-I region HG3 3.81E−05 10.17 12,937.3 1
TRFE_HUMAN Serotransferrin 4.38E−05 66.22 76,999.7 7
PROF1_HUMAN Profilin-1 4.39E−05 10.22 15,044.6 1
KV3I_HUMAN Ig kappa chain V-III region VG 8.00E−05 20.25 12,567.3 3
APOB_HUMAN Apolipoprotein B-100 8.41E−05 20.21 515,241.6 2
LV3A_HUMAN Ig lambda chain V-III region SH 8.52E−05 10.21 11,385.6 1
APOC3_HUMAN Apolipoprotein C-III 8.88E−05 10.16 10,845.5 1
PRDX6_HUMAN Peroxiredoxin-6 9.49E−05 10.14 25,019.2 1
DOPO_HUMAN Dopamine beta-hydroxylase 1.01E−04 20.16 69,020.8 2
KV1V_HUMAN Ig kappa chain V-I region BAN 1.47E−04 10.19 11,832.8 2
TRIM7_HUMAN Tripartite motif-containing protein 7 2.81E−04 10.15 56,595.0 6
SAA4_HUMAN Serum amyloid A-4 protein 3.43E−04 20.16 14,797.3 4
Fraction 33 proteins
HBA_HUMAN Hemoglobin subunit alpha 1.00E−30 350.39 15,247.9 127
PGRP2_HUMAN N-acetylmuramoyl-L-alanine amidase 1.11E−15 268.33 62,178.0 53
CFAB_HUMAN Complement factor B 1.11E−15 180.34 85,478.6 30
RETBP_PANTR Plasma retinol-binding protein 1.11E−15 70.32 22,995.3 30
APOA1_HUMAN Apolipoprotein A-I 8.88E−15 648.34 30,758.9 410
S10AC_HUMAN Protein S100-A12 1.22E−14 20.35 10,568.5 3
CO3_HUMAN Complement C3 2.11E−14 468.34 187,029.3 76
HEMO_HUMAN Hemopexin 6.33E−14 178.29 51,643.3 30
TTHY_HUMAN Transthyretin 1.45E−13 220.33 15,877.1 49
CFAI_HUMAN Complement factor I 2.96E−13 88.28 65,676.7 14
ENOA_HUMAN Alpha-enolase 3.60E−13 50.33 47,139.4 7
CERU_HUMAN Ceruloplasmin 3.69E−13 60.33 122,127.6 6
K2C1_HUMAN Keratin, type II cytoskeletal 1 3.94E−13 76.34 65,977.9 9
ITIH2_HUMAN Inter-alpha-trypsin inhibitor heavy chain H2 1.32E−12 50.33 106,369.8 6
ENOB_HUMAN Beta-enolase 1.48E−12 10.25 46,957.4 3
CO8G_HUMAN Complement component C8 gamma chain 3.98E−12 20.20 22,263.6 3
ANT3_HUMAN Antithrombin-III 4.03E−12 268.30 52,569.0 39
IGKC_HUMAN Ig kappa chain C region 4.14E−12 100.29 11,601.7 54
IGHA1_HUMAN Ig alpha-1 chain C region 1.07E−11 90.29 37,630.7 32
KV1D_HUMAN Ig kappa chain V-I region CAR 1.20E−11 20.26 11,696.3 3
APOM_HUMAN Apolipoprotein M 1.29E−11 60.25 21,239.4 8
CO4A_HUMAN Complement C4-A 1.48E−11 200.28 192,649.5 25
PSA2_HUMAN Proteasome subunit alpha type-2 1.55E−11 60.29 25,882.3 8
Clin Proteom (2009) 5:75–102 87
Table 1 (continued)
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HV3R_HUMAN Ig heavy chain V-III region TUR 2.17E−11 20.25 12,423.3 4
KV1R_HUMAN Ig kappa chain V-I region WEA 2.35E−11 26.28 11,832.8 8
HBB_HUMAN Hemoglobin subunit beta 3.15E−11 190.27 15,988.3 85
HBD_HUMAN Hemoglobin subunit delta 4.14E−11 228.29 16,045.3 66
GSTP1_HUMAN Glutathione S-transferase P 7.69E−11 30.25 23,341.0 4
LV4C_HUMAN Ig lambda chain V-IV region Hil 8.74E−11 20.26 11,509.6 4
FIBA_HUMAN Fibrinogen alpha chain 9.51E−11 20.26 94,914.3 2
APOC2_HUMAN Apolipoprotein C-II 1.01E−10 100.28 11,276.8 17
LAC_HUMAN Ig lambda chain C regions 1.09E−10 50.27 11,229.5 14
S10A9_HUMAN Protein S100-A9 1.16E−10 128.28 13,233.5 31
CLUS_HUMAN Clusterin 2.11E−10 218.30 52,461.1 47
SAMP_HUMAN Serum amyloid P-component 2.58E−10 10.19 25,371.1 2
HV3P_HUMAN Ig heavy chain V-III region TEI 4.78E−10 10.26 12,794.4 3
KV3H_HUMAN Ig kappa chain V-III region CLL 6.52E−10 10.21 14,266.2 2
PERM_HUMAN Myeloperoxidase 6.57E−10 10.21 83,815.0 1
ALBU_HUMAN Serum albumin 6.70E−10 190.27 69,321.6 44
SPB10_HUMAN Serpin B10 7.84E−10 30.21 45,374.0 3
CO6A1_HUMAN Collagen alpha-1(VI) chain 7.93E−10 20.26 108,462.0 3
A2GL_HUMAN Leucine-rich alpha-2-glycoprotein 8.29E−10 50.25 38,154.1 8
IGHA2_HUMAN Ig alpha-2 chain C region 1.05E−09 94.24 36,485.1 28
ITIH1_HUMAN Inter-alpha-trypsin inhibitor heavy chain H1 1.10E−09 30.26 101,325.8 3
KV1S_HUMAN Ig kappa chain V-I region Wes 1.21E−09 10.23 11,600.7 1
APOA2_HUMAN Apolipoprotein A-II 1.22E−09 100.28 11,167.9 13
CATD_HUMAN Cathepsin D 1.30E−09 32.22 44,523.7 4
A2MG_HUMAN Alpha-2-macroglobulin 1.34E−09 120.23 163,174.3 16
SHBG_HUMAN Sex hormone-binding globulin 1.66E−09 10.29 43,751.9 1
KV4C_HUMAN Ig kappa chain V-IV region B17 1.69E−09 30.24 14,956.5 5
TRFE_HUMAN Serotransferrin 4.52E−09 20.21 76,999.7 2
ITIH4_HUMAN Inter-alpha-trypsin inhibitor heavy chain H4 6.22E−09 110.26 103,261.2 16
MUCB_HUMAN Ig mu heavy chain disease protein 6.34E−09 68.25 43,030.3 20
S10A8_HUMAN Protein S100-A8 6.64E−09 20.25 10,827.7 2
HSP71_PONAB Heat shock 70 kDa protein 1 6.79E−09 20.27 70,009.2 2
HPT_HUMAN Haptoglobin 7.42E−09 132.26 45,176.6 24
KV3G_HUMAN Ig kappa chain V-III region GOL 7.50E−09 10.23 11,823.0 2
AFAM_HUMAN Afamin 2.07E−08 70.24 69,024.1 7
FIBB_HUMAN Fibrinogen beta chain 2.09E−08 70.24 55,892.2 8
K1C9_HUMAN Keratin, type I cytoskeletal 9 2.09E−08 40.33 62,091.8 4
TKT_HUMAN Transketolase 2.24E−08 40.21 67,834.9 5
IGHM_HUMAN Ig mu chain C region 2.76E−08 50.25 49,275.6 9
GELS_HUMAN Gelsolin 3.10E−08 10.23 85,644.3 1
FIBG_HUMAN Fibrinogen gamma chain 3.14E−08 50.19 51,478.9 5
IGHD_HUMAN Ig delta chain C region 3.27E−08 20.19 42,227.3 3
ADIPO_HUMAN Adiponectin 4.87E−08 10.23 26,397.0 1
PRDX2_HUMAN Peroxiredoxin-2 5.29E−08 50.21 21,878.2 6
LV3B_HUMAN Ig lambda chain V-III region LOI 7.16E−08 20.22 11,927.8 4
VASP_HUMAN Vasodilator-stimulated phosphoprotein 1.37E−07 30.25 39,805.1 5
PSA6_RAT Proteasome subunit alpha type-6 2.97E−07 10.17 27,381.8 1
ENO1B_HUMAN Alpha-enolase, lung specific 6.65E−07 10.26 49,446.4 1
HPTR_HUMAN Haptoglobin-related protein 6.93E−07 10.20 38,982.7 1
88 Clin Proteom (2009) 5:75–102
Table 1 (continued)
P (pro) Score MW Hits
IGHG3_HUMAN Ig gamma-3 chain C region 1.04E−06 20.18 41,260.4 2
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase 1.35E−06 20.22 36,030.4 3
KLKB1_HUMAN Plasma kallikrein 2.39E−06 10.18 71,322.8 1
ANXA1_HUMAN Annexin A1 2.64E−06 10.20 38,690.0 1
ANXA3_HUMAN Annexin A3 3.79E−06 24.18 36,352.7 3
AMPL_HUMAN Cytosol aminopeptidase 4.31E−06 10.14 56,130.9 1
S100P_HUMAN Protein S100-P 4.65E−06 10.18 10,393.2 1
MMP8_HUMAN Neutrophil collagenase 4.76E−06 30.23 53,378.6 3
APOE_HUMAN Apolipoprotein E 5.02E−06 50.21 36,131.8 6
HBG1_PANTR Hemoglobin subunit gamma-1 8.24E−06 20.16 16,130.3 2
KV1V_HUMAN Ig kappa chain V-I region BAN 9.89E−06 10.22 11,832.8 1
APOA4_HUMAN Apolipoprotein A-IV 1.25E−05 60.19 45,371.5 7
KV3I_HUMAN Ig kappa chain V-III region VG precursor 1.41E−05 20.23 12,567.3 3
HV3A_HUMAN Ig heavy chain V-III region TRO 1.43E−05 10.16 13,463.5 1
THBG_HUMAN Thyroxine-binding globulin 1.94E−05 10.20 46,294.7 1
K1C14_HUMAN Keratin, type I cytoskeletal 14 2.73E−05 10.13 51,589.5 1
IGLL1_HUMAN Immunoglobulin lambda-like polypeptide 1 3.37E−05 38.21 22,948.6 5
K1C10_HUMAN Keratin, type I cytoskeletal 10 5.01E−05 30.19 59,474.8 3
LV3A_HUMAN Ig lambda chain V-III region SH 8.87E−05 10.18 11,385.6 1
CRP_HUMAN C-reactive protein 2.33E−04 20.18 25,022.7 2
CBPN_HUMAN Carboxypeptidase N catalytic chain 2.42E−04 10.24 52,253.4 1
CAPG_HUMAN Macrophage-capping protein 2.55E−04 20.16 38,493.6 2
SAA4_HUMAN Serum amyloid A-4 protein 2.71E−04 20.14 14,797.3 2
MMP3_HUMAN Stromelysin-1 4.23E−04 10.13 53,943.4 1
GDIS_HUMAN Rho GDP-dissociation inhibitor 2 6.94E−04 20.25 22,973.6 2
HV3V_HUMAN Ig heavy chain V-III region GAR 8.20E−04 10.13 13,079.2 1
Fraction 34 proteins
CO3_HUMAN Complement C3 1.00E−30 576.33 187,029.3 99
HBA_HUMAN Hemoglobin subunit alpha 1.00E−30 230.37 15,247.9 91
TTHY_HUMAN Transthyretin 1.00E−30 150.33 15,877.1 28
CFAB_HUMAN Complement factor B 3.33E−15 120.35 85,478.6 20
PGRP2_HUMAN N-acetylmuramoyl-L-alanine amidase 8.88E−15 290.34 62,178.0 52
IGKC_HUMAN Ig kappa chain C region 1.11E−14 70.29 11,601.7 40
APOA1_HUMAN Apolipoprotein A-I 1.89E−14 862.32 30,758.9 660
ENOB_HUMAN Beta-enolase 2.34E−13 10.24 46,957.4 1
ENOA_HUMAN Alpha-enolase 4.31E−13 40.24 47,139.4 4
RETBP_PANTR Plasma retinol-binding protein 7.37E−13 58.31 22,995.3 20
KV4C_HUMAN Ig kappa chain V-IV region B17 8.39E−13 20.26 14,956.5 3
IGHA1_HUMAN Ig alpha-1 chain C region 9.03E−13 110.27 37,630.7 28
QSOX1_HUMAN Sulfhydryl oxidase 1 1.02E−12 60.29 82,525.7 6
HV3R_HUMAN Ig heavy chain V-III region TUR 1.09E−12 10.28 12,423.3 2
MMP8_HUMAN Neutrophil collagenase 1.19E−12 60.26 53,378.6 9
CO4A_HUMAN Complement C4-A 4.03E−12 190.32 192,649.5 21
ITIH1_HUMAN Inter-alpha-trypsin inhibitor heavy chain H1 4.04E−12 110.34 101,325.8 16
APOL1_HUMAN Apolipoprotein-L1 4.42E−12 10.28 43,947.0 1
CO6A1_HUMAN Collagen alpha-1(VI) chain 8.68E−12 40.32 108,462.0 6
LAC_HUMAN Ig lambda chain C regions 1.47E−11 50.28 11,229.5 20
CFAI_HUMAN Complement factor I 1.60E−11 66.24 65,676.7 10
ALBU_HUMAN Serum albumin 2.54E−11 150.26 69,321.6 27
Clin Proteom (2009) 5:75–102 89
Table 1 (continued)
P (pro) Score MW Hits
CBPB2_HUMAN Carboxypeptidase B2 3.13E−11 10.23 48,381.5 1
APOA2_HUMAN Apolipoprotein A-II 4.64E−11 118.31 11,167.9 24
HEMO_HUMAN Hemopexin 9.46E−11 100.31 51,643.3 16
S10A9_HUMAN Protein S100-A9 2.64E−10 136.27 13,233.5 33
HV3P_HUMAN Ig heavy chain V-III region TEI 3.69E−10 10.26 12,794.4 1
ITIH2_HUMAN Inter-alpha-trypsin inhibitor heavy chain H2 3.86E−10 30.29 106,369.8 3
GSTP1_HUMAN Glutathione S-transferase P 4.12E−10 30.26 23,341.0 3
PERM_HUMAN Myeloperoxidase 4.13E−10 90.26 83,815.0 10
FIBB_HUMAN Fibrinogen beta chain 4.90E−10 60.27 55,892.2 7
HBG1_PANTR Hemoglobin subunit gamma-1 5.83E−10 30.22 16,130.3 4
ANT3_HUMAN Antithrombin-III 7.22E−10 50.30 52,569.0 8
HBD_HUMAN Hemoglobin subunit delta 8.76E−10 108.31 16,045.3 20
ILEU_HUMAN Leukocyte elastase inhibitor 9.91E−10 10.24 42,714.8 1
KV1V_HUMAN Ig kappa chain V-I region BAN 1.08E−09 10.21 11,832.8 1
MUCB_HUMAN Ig mu heavy chain disease protein 1.48E−09 78.23 43,030.3 14
IGHA2_HUMAN Ig alpha-2 chain C region 1.79E−09 98.22 36,485.1 28
APOC2_HUMAN Apolipoprotein C-II 2.18E−09 30.26 11,276.8 3
IGHM_HUMAN Ig mu chain C region 2.74E−09 40.24 49,275.6 9
ANXA1_HUMAN Annexin A1 3.24E−09 80.27 38,690.0 13
CLUS_HUMAN Clusterin 4.75E−09 10.22 52,461.1 2
KV3H_HUMAN Ig kappa chain V-III region CLL 5.07E−09 10.25 14,266.2 1
HBB_HUMAN Hemoglobin subunit beta 6.68E−09 80.27 15,988.3 18
IGHD_HUMAN Ig delta chain C region 7.74E−09 20.19 42,227.3 2
FIBA_HUMAN Fibrinogen alpha chain 9.00E−09 20.27 94,914.3 2
ANXA3_HUMAN Annexin A3 9.98E−09 48.24 36,352.7 5
IGHG3_HUMAN Ig gamma-3 chain C region 1.14E−08 10.19 41,260.4 1
A2AP_HUMAN Alpha-2-antiplasmin 1.51E−08 20.24 54,531.2 3
APOM_HUMAN Apolipoprotein M 1.72E−08 30.25 21,239.4 3
CO6A3_HUMAN Collagen alpha-3(VI) chain 1.86E−08 34.23 343,337.4 4
K2C1_HUMAN Keratin, type II cytoskeletal 1 3.05E−08 20.35 65,977.9 3
FIBG_HUMAN Fibrinogen gamma chain 3.23E−08 20.22 51,478.9 2
LV4C_HUMAN Ig lambda chain V-IV region Hil 3.65E−08 10.26 11,509.6 3
CO8G_HUMAN Complement component C8 gamma chain 3.98E−08 30.22 22,263.6 4
APOE_HUMAN Apolipoprotein E 4.02E−08 60.27 36,131.8 8
APOA4_HUMAN Apolipoprotein A-IV 4.26E−08 146.23 45,371.5 22
A2MG_HUMAN Alpha-2-macroglobulin 4.73E−08 90.22 163,174.3 9
LV3B_HUMAN Ig lambda chain V-III region LOI 6.46E−08 20.24 11,927.8 2
KV3G_HUMAN Ig kappa chain V-III region GOL 8.44E−08 10.24 11,823.0 1
KV1S_HUMAN Ig kappa chain V-I region Wes 1.74E−07 10.28 11,600.7 1
HPTR_HUMAN Haptoglobin-related protein 2.32E−07 10.20 38,982.7 1
PRDX2_HUMAN Peroxiredoxin-2 4.68E−07 40.22 21,878.2 5
K1C10_HUMAN Keratin, type I cytoskeletal 10 7.41E−07 20.19 59,474.8 2
ITIH4_HUMAN Inter-alpha-trypsin inhibitor heavy chain H4 7.44E−07 100.25 103,261.2 11
A1AT_HUMAN Alpha-1-antitrypsin 9.34E−07 10.18 46,707.1 1
HMOX1_HUMAN Heme oxygenase 1 1.60E−06 10.20 32,798.0 1
IGJ_HUMAN Immunoglobulin J chain 1.88E−06 10.15 15,584.6 2
ACTB_HUMAN Actin, cytoplasmic 1 3.59E−06 30.19 41,709.7 3
CFAH_HUMAN Complement factor H 5.24E−06 10.16 139,004.4 1
AFAM_HUMAN Afamin 5.26E−06 10.19 69,024.1 1
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TRFE_HUMAN Serotransferrin 5.69E−06 10.19 76,999.7 1
A2GL_HUMAN Leucine-rich alpha-2-glycoprotein 6.14E−06 20.21 38,154.1 2
CO9_HUMAN Complement component C9 7.89E−06 20.21 63,132.8 2
KV3I_HUMAN Ig kappa chain V-III region VG 9.13E−06 20.24 12,567.3 2
KV2F_HUMAN Ig kappa chain V-II region RPMI 6410 1.13E−05 10.13 14,697.4 1
MMP3_HUMAN Stromelysin-1 2.47E−05 10.17 53,943.4 1
HPT_HUMAN Haptoglobin 2.94E−05 74.19 45,176.6 13
S10A8_HUMAN Protein S100-A8 2.99E−05 10.19 10,827.7 3
HV1B_HUMAN Ig heavy chain V-I region HG3 5.54E−05 10.16 12,937.3 1
S11Y_HUMAN Putative S100 calcium-binding protein H_NH0456N16.1 6.65E−05 10.20 11,501.9 1
GGH_HUMAN Gamma-glutamyl hydrolase 7.09E−05 40.19 35,941.2 4
SAMP_HUMAN Serum amyloid P-component 2.25E−04 30.14 25,371.1 3
PROF1_HUMAN Profilin-1 3.64E−04 10.23 15,044.6 1
KV1F_HUMAN Ig kappa chain V-I region EU 5.68E−04 10.16 11,780.8 1
S100P_HUMAN Protein S100-P 6.18E−04 10.18 10,393.2 1
TRIM7_HUMAN Tripartite motif-containing protein 7 8.38E−04 10.16 56,595.0 2
Fraction 35 proteins
A2AP_HUMAN Alpha-2-antiplasmin 1.00E−30 50.30 54,531.2 9
HBA_HUMAN Hemoglobin subunit alpha 5.55E−15 50.32 15,247.9 8
APOA1_HUMAN Apolipoprotein A-I 5.83E−15 1,010.32 30,758.9 1,258
CO3_HUMAN Complement C3 1.44E−14 190.35 187,029.3 28
A2MG_HUMAN Alpha-2-macroglobulin 1.44E−14 60.37 163,174.3 6
ACTB_HUMAN Actin, cytoplasmic 1 2.23E−13 20.34 41,709.7 2
IGKC_HUMAN Ig kappa chain C region 2.95E−13 30.25 11,601.7 22
S10A6_HUMAN Protein S100-A6 3.49E−13 30.26 10,173.3 4
K2C1_HUMAN Keratin, type II cytoskeletal 1 1.93E−12 20.25 65,977.9 2
FRIL_HUMAN Ferritin light chain 3.90E−12 14.27 20,007.1 3
APOA2_HUMAN Apolipoprotein A-II 1.08E−11 110.31 11,167.9 17
TTHY_HUMAN Transthyretin 1.16E−11 70.30 15,877.1 14
LAC_HUMAN Ig lambda chain C regions 4.68E−11 20.30 11,229.5 13
PGRP2_HUMAN N-acetylmuramoyl-L-alanine amidase 5.23E−11 30.29 62,178.0 3
HV3P_HUMAN Ig heavy chain V-III region TEI 9.68E−11 10.26 12,794.4 1
HBD_HUMAN Hemoglobin subunit delta 3.71E−10 28.26 16,045.3 3
CO4A_HUMAN Complement C4-A 6.90E−10 40.25 192,649.5 4
IGHA2_HUMAN Ig alpha-2 chain C region 1.08E−09 58.22 36,485.1 13
MUCB_HUMAN Ig mu heavy chain disease protein 1.21E−09 48.26 43,030.3 6
ILEU_HUMAN Leukocyte elastase inhibitor 1.50E−09 30.23 42,714.8 3
KV1D_HUMAN Ig kappa chain V-I region CAR 2.61E−09 10.27 11,696.3 3
KAIN_HUMAN Kallistatin 3.73E−09 50.22 48,511.2 6
HEMO_HUMAN Hemopexin 4.23E−09 30.23 51,643.3 3
S10A8_HUMAN Protein S100-A8 5.29E−09 10.24 10,827.7 1
ALBU_HUMAN Serum albumin 7.79E−09 40.24 69,321.6 5
HBB_HUMAN Hemoglobin subunit beta 1.31E−08 30.26 15,988.3 4
APOA4_HUMAN Apolipoprotein A-IV 2.29E−08 40.23 45,371.5 9
IGHA1_HUMAN Ig alpha-1 chain C region 2.35E−08 40.27 37,630.7 5
CFAI_HUMAN Complement factor I 2.62E−08 20.23 65,676.7 2
ITIH1_HUMAN Inter-alpha-trypsin inhibitor heavy chain H1 5.56E−08 20.23 101,325.8 2
KV3H_HUMAN Ig kappa chain V-III region CLL 7.79E−08 10.25 14,266.2 1
APOE_HUMAN Apolipoprotein E 1.90E−07 20.27 36,131.8 3
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ITIH4_HUMAN Inter-alpha-trypsin inhibitor heavy chain H4 2.81E−07 30.21 103,261.2 3
CFAB_HUMAN Complement factor B 3.03E−07 30.24 85,478.6 4
IGHM_HUMAN Ig mu chain C region 3.85E−07 30.23 49,275.6 5
LV3B_HUMAN Ig lambda chain V-III region LOI 1.97E−06 10.25 11,927.8 2
CO6A3_HUMAN Collagen alpha-3(VI) chain 2.12E−06 44.24 343,337.4 6
HV3R_HUMAN Ig heavy chain V-III region TUR 2.31E−06 10.20 12,423.3 1
HPT_HUMAN Haptoglobin 4.31E−06 20.18 45,176.6 3
FIBA_HUMAN Fibrinogen alpha chain 1.10E−05 10.21 94,914.3 1
LV4C_HUMAN Ig lambda chain V-IV region Hil 2.21E−05 10.22 11,509.6 1
APOM_HUMAN Apolipoprotein M 3.10E−05 10.24 21,239.4 1
PLMN_HUMAN Plasminogen 4.83E−05 10.22 90,510.2 1
RETBP_PANTR Plasma retinol-binding protein 5.79E−05 20.15 22,995.3 3
Fraction 36 proteins
CO3_HUMAN Complement C3 1.00E−30 220.30 187,029.3 29
IGHA2_HUMAN Ig alpha-2 chain C region 1.00E−30 70.34 36,485.1 20
CO4B_HUMAN Complement C4-B 2.22E−15 10.33 192,671.6 1
HBA_HUMAN Hemoglobin subunit alpha 5.55E−15 50.33 15,247.9 8
ACTB_HUMAN Actin, cytoplasmic 1 7.77E−15 30.32 41,709.7 4
A2MG_HUMAN Alpha-2-macroglobulin 2.22E−14 100.32 163,174.3 17
APOA1_HUMAN Apolipoprotein A-I 6.08E−14 1,012.33 30,758.9 1,155
A2AP_HUMAN Alpha-2-antiplasmin 1.15E−13 136.34 54,531.2 20
HEMO_HUMAN Hemopexin 1.15E−13 50.21 51,643.3 5
ITIH1_HUMAN Inter-alpha-trypsin inhibitor heavy chain H1 1.77E−13 10.24 101,325.8 1
K1C9_HUMAN Keratin, type I cytoskeletal 9 3.15E−13 10.38 62,091.8 1
KAIN_HUMAN Kallistatin 6.87E−13 140.28 48,511.2 26
PLMN_HUMAN Plasminogen 1.32E−12 30.32 90,510.2 3
APOA2_HUMAN Apolipoprotein A-II 3.83E−12 248.32 11,167.9 167
KV4C_HUMAN Ig kappa chain V-IV region B17 3.96E−12 10.28 14,956.5 1
IGKC_HUMAN Ig kappa chain C region 3.97E−12 40.26 11,601.7 23
RETBP_PANTR Plasma retinol-binding protein 5.60E−12 40.31 22,995.3 7
K2C1_HUMAN Keratin, type II cytoskeletal 1 1.01E−11 30.37 65,977.9 4
APOA4_HUMAN Apolipoprotein A-IV 1.79E−11 70.28 45,371.5 14
LAC_HUMAN Ig lambda chain C regions 6.60E−11 30.30 11,229.5 13
KV1D_HUMAN Ig kappa chain V-I region CAR 6.89E−11 10.29 11,696.3 1
HV3P_HUMAN Ig heavy chain V-III region TEI 7.58E−11 10.30 12,794.4 1
HBB_HUMAN Hemoglobin subunit beta 3.96E−10 70.27 15,988.3 13
FRIL_HUMAN Ferritin light chain 4.07E−10 36.27 20,007.1 7
TTHY_HUMAN Transthyretin 4.79E−10 50.31 15,877.1 6
CFAB_HUMAN Complement factor B 7.78E−10 20.25 85,478.6 2
AMBP_HUMAN AMBP protein 1.37E−09 10.25 38,974.0 1
ALBU_HUMAN Serum albumin 1.37E−09 70.24 69,321.6 9
MUCB_HUMAN Ig mu heavy chain disease protein 3.44E−09 38.22 43,030.3 6
KV3H_HUMAN Ig kappa chain V-III region CLL 4.18E−09 10.24 14,266.2 1
A1AT_HUMAN Alpha-1-antitrypsin 4.96E−09 20.23 46,707.1 2
APOL1_HUMAN Apolipoprotein-L1 5.95E−09 30.29 43,947.0 4
CO6A3_HUMAN Collagen alpha-3(VI) chain 7.12E−09 48.23 343,337.4 6
S10A9_HUMAN Protein S100-A9 8.28E−09 10.26 13,233.5 1
CFAI_HUMAN Complement factor I 1.04E−08 46.24 65,676.7 5
IGHG3_HUMAN Ig gamma-3 chain C region 1.24E−08 10.17 41,260.4 1
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FIBA_HUMAN Fibrinogen alpha chain 1.61E−08 20.22 94,914.3 2
APOE_HUMAN Apolipoprotein E 3.40E−08 20.27 36,131.8 3
IGHA1_HUMAN Ig alpha-1 chain C region 6.15E−08 30.24 37,630.7 5
IGHM_HUMAN Ig mu chain C region 1.50E−07 40.24 49,275.6 8
ACTS_HUMAN Actin, alpha skeletal muscle 2.46E−07 50.23 42,023.9 6
TALDO_HUMAN Transaldolase 2.88E−07 20.19 37,516.5 2
ANT3_HUMAN Antithrombin-III 1.16E−06 10.22 52,569.0 1
CO4A_HUMAN Complement C4-A 6.92E−06 26.18 192,649.5 3
CO8G_HUMAN Complement component C8 gamma chain 1.20E−05 10.20 22,263.6 1
HPT_HUMAN Haptoglobin 1.99E−05 28.19 45,176.6 4
ILEU_HUMAN Leukocyte elastase inhibitor 2.13E−05 20.23 42,714.8 2
IGJ_HUMAN Immunoglobulin J chain 2.93E−05 10.16 15,584.6 1
LV3B_HUMAN Ig lambda chain V-III region LOI 3.63E−05 10.20 11,927.8 1
M6PBP_HUMAN Mannose-6-phosphate receptor-binding protein 1 3.95E−04 10.22 47,018.0 1
PROF1_HUMAN Profilin-1 7.14E−04 10.20 15,044.6 1
Fraction 37 proteins
IGHA1_HUMAN Ig alpha-1 chain C region 1.00E−30 70.29 37,630.7 17
K2C1_HUMAN Keratin, type II cytoskeletal 1 1.11E−16 60.39 65,977.9 7
ACTB_HUMAN Actin, cytoplasmic 1 5.55E−16 150.32 41,709.7 19
K1C9_HUMAN Keratin, type I cytoskeletal 9 1.11E−15 44.38 62,091.8 6
APOB_HUMAN Apolipoprotein B-100 1.33E−15 398.38 515,241.6 53
A2AP_HUMAN Alpha-2-antiplasmin 3.33E−15 222.33 54,531.2 32
PLMN_HUMAN Plasminogen 4.44E−15 50.33 90,510.2 8
CO3_HUMAN Complement C3 9.88E−15 352.35 187,029.3 49
APOE_HUMAN Apolipoprotein E 7.77E−14 50.29 36,131.8 5
IGKC_HUMAN Ig kappa chain C region 1.58E−13 70.30 11,601.7 30
LKHA4_HUMAN Leukotriene A-4 hydrolase 1.75E−13 50.26 69,241.3 5
PGRP2_HUMAN N-acetylmuramoyl-L-alanine amidase 3.96E−13 20.27 62,178.0 2
APOL1_HUMAN Apolipoprotein-L1 4.22E−13 150.31 43,947.0 23
A2MG_HUMAN Alpha-2-macroglobulin 5.13E−13 380.37 163,174.3 58
ANGT_HUMAN Angiotensinogen 2.56E−12 50.31 53,120.6 5
CO4A_HUMAN Complement C4-A 5.35E−12 36.27 192,649.5 4
KAIN_HUMAN Kallistatin 6.59E−12 40.30 48,511.2 5
APOA2_HUMAN Apolipoprotein A-II 8.45E−12 174.33 11,167.9 68
APOA1_HUMAN Apolipoprotein A-I 8.67E−12 912.32 30,758.9 918
PLTP_HUMAN Phospholipid transfer protein 2.02E−11 30.26 54,704.7 3
KV4C_HUMAN Ig kappa chain V-IV region B17 2.83E−11 20.26 14,956.5 3
S10A6_HUMAN Protein S100-A6 2.88E−11 10.25 10,173.3 1
CO5_HUMAN Complement C5 2.96E−11 110.25 188,185.3 11
RETBP_PANTR Plasma retinol-binding protein 3.46E−11 50.29 22,995.3 12
HBA_HUMAN Hemoglobin subunit alpha 5.76E−11 30.20 15,247.9 5
ITIH1_HUMAN Inter-alpha-trypsin inhibitor heavy chain H1 6.33E−11 10.30 101,325.8 1
LAC_HUMAN Ig lambda chain C regions 8.48E−11 50.30 11,229.5 15
KV1D_HUMAN Ig kappa chain V-I region CAR 1.34E−10 20.26 11,696.3 4
HEMO_HUMAN Hemopexin 1.43E−10 88.25 51,643.3 11
CO6A3_HUMAN Collagen alpha-3(VI) chain 1.90E−10 38.22 343,337.4 5
HV3R_HUMAN Ig heavy chain V-III region TUR 2.35E−10 10.26 12,423.3 1
ITIH2_HUMAN Inter-alpha-trypsin inhibitor heavy chain H2 3.54E−10 100.25 106,369.8 15
TTHY_HUMAN Transthyretin 3.86E−10 30.34 15,877.1 4
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Table 1 (continued)
P (pro) Score MW Hits
HBD_HUMAN Hemoglobin subunit delta 4.49E−10 38.25 16,045.3 6
AMBP_HUMAN AMBP protein 7.76E−10 10.24 38,974.0 1
CO8G_HUMAN Complement component C8 gamma chain 8.36E−10 30.23 22,263.6 4
IGHA2_HUMAN Ig alpha-2 chain C region 4.57E−09 68.25 36,485.1 13
ALBU_HUMAN Serum albumin 4.66E−09 60.24 69,321.6 7
HBB_HUMAN Hemoglobin subunit beta 5.88E−09 40.27 15,988.3 6
FIBB_HUMAN Fibrinogen beta chain 7.26E−09 10.24 55,892.2 1
CFAI_HUMAN Complement factor I 1.06E−08 46.21 65,676.7 5
MUCB_HUMAN Ig mu heavy chain disease protein 1.38E−08 58.24 43,030.3 11
LV3B_HUMAN Ig lambda chain V-III region LOI 1.87E−08 10.23 11,927.8 1
POSTN_HUMAN Periostin 2.21E−08 34.25 93,255.4 5
KV3H_HUMAN Ig kappa chain V-III region CLL 2.88E−08 10.24 14,266.2 1
S10A9_HUMAN Protein S100-A9 3.71E−08 20.17 13,233.5 2
IGHM_HUMAN Ig mu chain C region 4.69E−08 30.24 49,275.6 7
KV3G_HUMAN Ig kappa chain V-III region GOL 5.54E−08 10.22 11,823.0 1
FIBA_HUMAN Fibrinogen alpha chain 7.08E−08 20.26 94,914.3 2
CO2_HUMAN Complement C2 7.13E−08 20.22 83,214.4 2
LDHB_HUMAN L-lactate dehydrogenase B chain 8.55E−08 10.18 36,615.2 1
PEDF_HUMAN Pigment epithelium-derived factor 9.52E−08 30.17 46,313.4 3
AACT_HUMAN Alpha-1-antichymotrypsin 1.12E−07 10.27 47,620.6 1
ITIH4_HUMAN Inter-alpha-trypsin inhibitor heavy chain H4 1.20E−07 20.22 103,261.2 3
ANT3_HUMAN Antithrombin-III 1.79E−07 10.27 52,569.0 1
KV1V_HUMAN Ig kappa chain V-I region BAN 2.30E−07 10.22 11,832.8 1
ACTS_HUMAN Actin, alpha skeletal muscle 2.70E−07 96.22 42,023.9 14
APOA4_HUMAN Apolipoprotein A-IV 3.06E−07 30.18 45,371.5 4
HRG_HUMAN Histidine-rich glycoprotein 8.44E−07 10.18 59,540.9 1
ADIPO_HUMAN Adiponectin 8.48E−07 10.23 26,397.0 1
HV3P_HUMAN Ig heavy chain V-III region TEI 1.03E−06 10.26 12,794.4 1
SAMP_HUMAN Serum amyloid P-component 2.09E−06 10.17 25,371.1 1
TALDO_HUMAN Transaldolase 2.15E−06 30.20 37,516.5 5
KV3I_HUMAN Ig kappa chain V-III region VG 6.88E−06 10.23 12,567.3 2
VINC_HUMAN Vinculin 8.61E−06 30.23 123,721.9 3
LDHA_HUMAN L-lactate dehydrogenase A chain 1.07E−05 10.15 36,665.4 1
IGJ_HUMAN Immunoglobulin J chain 1.38E−05 10.15 15,584.6 1
HPT_HUMAN Haptoglobin 2.95E−05 64.24 45,176.6 7
FA12_HUMAN Coagulation factor XII 3.00E−05 10.23 67,774.1 1
LV4C_HUMAN Ig lambda chain V-IV region Hil 3.06E−05 10.20 11,509.6 1
PROF1_HUMAN Profilin-1 1.12E−04 10.21 15,044.6 1
HV3A_HUMAN Ig heavy chain V-III region TRO 1.46E−04 10.16 13,463.5 1
BGH3_HUMAN Transforming growth factor-beta-induced protein ig-h3 1.76E−04 10.18 74,634.1 1
CSN8_HUMAN COP9 signalosome complex subunit 8 1.78E−04 10.16 23,211.0 1
O52A5_HUMAN Olfactory receptor 52A5 3.20E−04 10.12 35,931.3 1
Fraction 38 proteins
A2AP_HUMAN Alpha-2-antiplasmin 1.11E−16 108.31 54,531.2 15
A2MG_HUMAN Alpha-2-macroglobulin 2.22E−15 538.38 163,174.3 88
APOA1_HUMAN Apolipoprotein A-I 2.55E−14 350.33 30,758.9 389
IGHA1_HUMAN Ig alpha-1 chain C region 3.00E−14 40.25 37,630.7 16
PGRP2_HUMAN N-acetylmuramoyl-L-alanine amidase 6.44E−14 10.29 62,178.0 3
ACTB_HUMAN Actin, cytoplasmic 1 1.98E−13 90.32 41,709.7 13
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Table 1 (continued)
P (pro) Score MW Hits
K2C1_HUMAN Keratin, type II cytoskeletal 1 3.56E−13 130.36 65,977.9 16
APOL1_HUMAN Apolipoprotein-L1 1.43E−12 80.29 43,947.0 10
PLMN_HUMAN Plasminogen 1.47E−12 20.31 90,510.2 3
IGKC_HUMAN Ig kappa chain C region 5.07E−12 60.29 11,601.7 43
HV3R_HUMAN Ig heavy chain V-III region TUR 5.17E−12 10.29 12,423.3 2
K1C10_HUMAN Keratin, type I cytoskeletal 10 5.49E−12 80.31 59,474.8 9
TLN1_HUMAN Talin-1 5.71E−12 40.28 269,596.3 5
APOB_HUMAN Apolipoprotein B-100 6.46E−12 498.35 515,241.6 82
HBA_HUMAN Hemoglobin subunit alpha 2.90E−11 50.30 15,247.9 8
CO3_HUMAN Complement C3 2.99E−11 480.30 187,029.3 69
KV4C_HUMAN Ig kappa chain V-IV region B17 5.13E−11 40.24 14,956.5 5
LV4C_HUMAN Ig lambda chain V-IV region Hil 7.27E−11 10.24 11,509.6 1
LAC_HUMAN Ig lambda chain C regions 1.33E−10 20.28 11,229.5 17
APOA2_HUMAN Apolipoprotein A-II 1.34E−10 120.32 11,167.9 20
TTHY_HUMAN Transthyretin 2.49E−10 60.23 15,877.1 8
HEMO_HUMAN Hemopexin 2.93E−10 60.25 51,643.3 15
S10A6_HUMAN Protein S100-A6 4.78E−10 20.22 10,173.3 2
ACTS_HUMAN Actin, alpha skeletal muscle 1.07E−09 28.20 42,023.9 4
RETBP_PANTR Plasma retinol-binding protein 1.47E−09 100.30 22,995.3 31
ENOA_HUMAN Alpha-enolase 1.49E−09 30.24 47,139.4 3
ANT3_HUMAN Antithrombin-III 2.72E−09 20.25 52,569.0 2
HBB_HUMAN Hemoglobin subunit beta 3.32E−09 50.25 15,988.3 12
CFAB_HUMAN Complement factor B 3.59E−09 40.23 85,478.6 4
S10A9_HUMAN Protein S100-A9 3.63E−09 20.21 13,233.5 2
K1C9_HUMAN Keratin, type I cytoskeletal 9 4.51E−09 90.40 62,091.8 13
CO8G_HUMAN Complement component C8 gamma chain 5.21E−09 30.21 22,263.6 3
CO5_HUMAN Complement C5 6.03E−09 160.23 188,185.3 17
DCTN2_HUMAN Dynactin subunit 2 9.83E−09 30.20 44,203.9 3
CO6A3_HUMAN Collagen alpha-3(VI) chain 1.06E−08 10.19 343,337.4 1
MUCB_HUMAN Ig mu heavy chain disease protein 1.58E−08 68.23 43,030.3 23
CO4A_HUMAN Complement C4-A 1.67E−08 62.23 192,649.5 7
IGHA2_HUMAN Ig alpha-2 chain C region 1.83E−08 100.23 36,485.1 20
IGHM_HUMAN RecName: Full=Ig mu chain C region 2.08E−08 30.23 49,275.6 9
HRG_HUMAN Histidine-rich glycoprotein 2.20E−08 20.23 59,540.9 2
6PGD_HUMAN 6-phosphogluconate dehydrogenase, decarboxylating 2.72E−08 10.23 53,106.0 1
SAMP_HUMAN Serum amyloid P-component 2.99E−08 30.20 25,371.1 4
ITIH4_HUMAN Inter-alpha-trypsin inhibitor heavy chain H4 5.84E−08 30.22 103,261.2 3
TKT_HUMAN Transketolase 7.66E−08 20.19 67,834.9 3
BGH3_HUMAN Transforming growth factor-beta-induced protein ig-h3 1.10E−07 40.20 74,634.1 4
ALBU_HUMAN Serum albumin 1.25E−07 130.25 69,321.6 18
SPB9_HUMAN Serpin B9 1.27E−07 80.19 42,376.4 8
HBD_HUMAN Hemoglobin subunit delta 1.52E−07 28.19 16,045.3 3
APOA4_HUMAN Apolipoprotein A-IV 2.42E−07 40.20 45,371.5 4
APOE_HUMAN Apolipoprotein E 2.58E−07 20.25 36,131.8 2
HPT_HUMAN Haptoglobin 2.74E−07 102.23 45,176.6 18
CFAI_HUMAN Complement factor I 2.85E−07 56.23 65,676.7 8
ADIPO_HUMAN Adiponectin 4.68E−07 10.23 26,397.0 1
ANGT_HUMAN Angiotensinogen 4.90E−07 30.22 53,120.6 3
IGLL1_HUMAN Immunoglobulin lambda-like polypeptide 1 7.41E−07 10.19 22,948.6 1
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the protein array analysis, the mass spectrometry analysis
did not yield a protein identification. Both the protein
arrays and HPLC chromatographs appear to be more
sensitive at detecting proteins than the mass spectrometry.
In order to obtain enough material for mass spectrometry
analysis, SF from nine different patients was pooled (total
volume of 50 ml) and used for a large-scale procedure. After
protein depletion, approximately 20 mg of depleted SF
material was used to perform four first-dimension chroma-
tofocusing runs (Fig. 3a). The fractions that eluted at pH
5.63–5.45 were combined to perform one second-dimension
RP-HPLC run (Fig. 3b). Fractions corresponding to the
region that tested positive for RA serum binding in the
protein array were digested with trypsin and analyzed by LC/
MS/MS. SEQUEST searches were performed using the
SwissProt database limiting the search to tryptic peptides.
Table 1 lists the proteins found in these fractions and the
corresponding peptides are included as supplementary
material (Supplement Table 1).
The candidate autoantigen specifically detected by the
RA serum was estimated to be in fractions 20–22. Amongst
other proteins, these fractions contained fibrinogen, a
known autoantigen that can be citrullinated in vivo.
Fibrinogen alpha (FIBA_HUMAN, SwissProt Accession #
P02671) was identified in fraction 20 with nine unique
peptide hits (15% sequence coverage) and in fraction 22
with 18 unique peptides (24% sequence coverage). Alto-
gether, peptides were only found originating from the
center of the FIBA protein (amino acids 250–599)
corresponding to the alphaC domain of fibrin (amino acids
239–629). Figure 4 shows the sequence of the fibrin alphaC
domain with the amino acids identified by mass spectrom-
Table 1 (continued)
P (pro) Score MW Hits
ENO1B_HUMAN Alpha-enolase, lung specific 9.50E−07 20.24 49,446.4 2
PEDF_HUMAN Pigment epithelium-derived factor 9.80E−07 46.18 46,313.4 5
KV3G_HUMAN Ig kappa chain V-III region GOL 1.03E−06 10.19 11,823.0 2
KAIN_HUMAN Kallistatin 1.10E−06 10.20 48,511.2 1
ENOB_HUMAN Beta-enolase 1.18E−06 10.23 46,957.4 2
S10A8_HUMAN Protein S100-A8 1.41E−06 10.22 10,827.7 1
KV1D_HUMAN Ig kappa chain V-I region CAR 2.42E−06 20.24 11,696.3 2
LV3B_HUMAN Ig lambda chain V-III region LOI 2.43E−06 30.24 11,927.8 4
IGJ_HUMAN Immunoglobulin J chain 3.40E−06 10.16 15,584.6 1
ITIH2_HUMAN Inter-alpha-trypsin inhibitor heavy chain H2 4.00E−06 40.20 106,369.8 4
K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal 6.60E−06 20.23 65,825.4 2
HV3P_HUMAN Ig heavy chain V-III region TEI 8.90E−06 10.26 12,794.4 3
PSME1_HUMAN Proteasome activator complex subunit 1 9.97E−06 20.15 28,705.0 2
PLTP_HUMAN Phospholipid transfer protein 1.10E−05 40.20 54,704.7 5
CO2_HUMAN Complement C2 1.43E−05 10.23 83,214.4 1
KV3H_HUMAN Ig kappa chain V-III region CLL 1.66E−05 20.19 14,266.2 2
TETN_HUMAN Tetranectin 1.82E−05 10.18 22,552.3 1
LV3A_HUMAN Ig lambda chain V-III region SH 1.87E−05 10.21 11,385.6 2
LDHA_HUMAN L-lactate dehydrogenase A chain 1.89E−05 10.19 36,665.4 1
LDHB_HUMAN L-lactate dehydrogenase B chain 2.04E−05 30.22 36,615.2 3
C1QB_HUMAN Complement C1q subcomponent subunit B 3.63E−05 10.23 26,442.4 1
ILEU_HUMAN Leukocyte elastase inhibitor 5.71E−05 10.17 42,714.8 1
IPSP_HUMAN Plasma serine protease inhibitor 7.70E−05 10.16 45,672.8 1
IGHD_HUMAN Ig delta chain C region 1.11E−04 10.17 42,227.3 1
FIBB_HUMAN Fibrinogen beta chain 2.02E−04 10.18 55,892.2 1
IGHG3_HUMAN Ig gamma-3 chain C region 2.10E−04 10.16 41,260.4 1
HV3V_HUMAN Ig heavy chain V-III region GAR 2.52E−04 10.17 13,079.2 1
HPTR_HUMAN Haptoglobin-related protein 2.62E−04 10.20 38,982.7 1
C1QC_HUMAN Complement C1q subcomponent subunit C 2.92E−04 10.19 25,757.1 1
KV3I_HUMAN Ig kappa chain V-III region VG 3.01E−04 10.20 12,567.3 1
PROF1_HUMAN Profilin-1 3.49E−04 10.17 15,044.6 1
K1C25_HUMAN Keratin, type I cytoskeletal 25 7.85E−04 10.15 49,287.4 1
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etry in bold and arrows pointing to any modifications.
Peptides from the center region were not identified due a
lysine-/arginine-rich area followed by two cross-linked
amino acids (Ser461–Ser491).
Careful examination of the mass spectra assigned to
arginine-containing FIBA peptides led to the assignment of
a citrullinated peptide corresponding to FIBA 259–287.
The calculated mass obtained from the mass spectrum
(Fig. 5) was 1 Da higher than the calculated mass for the
unmodified peptide. The lower resolution MS/MS spectrum
obtained with the ion trap part of the LTQ-FT did not allow
determination of the exact location of the modification.
However, a number of other fragments corresponding to
parts of the peptide (Table 2) were observed in the spectra
obtained with the ion cyclotron resonance (ICR) analyzer
of the LTQ-FT, which provided precise mass measure-
ments. There are four sites on the FIBA 259–287 peptide
that could possibly be modified resulting in a mass shift
of +1 Da. The peptide contains three arginines that can
be citrullinated and an asparagine that can be deaminated
to form aspartic acid (Fig. 5). All fragments that did not
show the expected tryptic cleavage at Arg 271 showed
observed masses that were 1 Da higher than the expected
mass for the unmodified form. This is consistent with the
known failure of trypsin to cleave citrullinated Arg
residues. Thus, only conversion of Arg 271 to citrulline is
   
←
← ← ← ← ←
← ← ← ← ← ←
← ← ←
← ← ← ← ←
← ← ←
← ← ← ← ← ←← ← ← ←
← ←
Fig. 4 The fibrin alphaC do-
main (239–629) with the regions
identified by mass spectrometry
in bold and the FIBA 259–287
underlined. Arrows point to
modifications
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consistent with observed mass values of this FIBA
fragment in RA SF and the failure of trypsin to cleave at
that site.
As a final proof that the citrullination site was correctly
assigned, the peptide corresponding to residues 259–287
was synthesized with and without the citrulline in position
271 (designated 271X and 271R, respectively). Both the
charge state distribution in the electrospray spectrum and
the fragment masses in the MS/MS spectrum of the 3+
charge state of 271X matched spectral data obtained with
the sample isolated from RA SF.
To establish that the citrullinated FIBA 259–287 peptide
was recognized specifically by RA patient sera, the two
FIBA 259–287 synthetic peptides were tested in an ELISA.
An additional citrullinated synthetic peptide, corresponding
to profilaggrin 619–631 (FIL) with a citrulline substitution
at Arg 625, was included as a control. The immobilized
peptides were incubated with sera from RA, SLE, or
healthy controls, followed by detection of bound antibodies
by HRP-conjugated anti-human IgG, IgA, and IgM anti-
bodies and a colorimetric assay. Graphs depicting the
ELISA optical density readings are shown in Fig. 6. Of
18 healthy control sera tested, two reacted to the 271R
peptide, two reacted to the 271X peptide, and one reacted to
the FIL peptide. Of the 12 RA sera tested, four reacted to
the 271R peptide, 10 reacted to the 271X peptide, and three
reacted to the FIL peptide. Of the 10 SLE sera tested, one
patient reacted to all three peptides. The number of sera that
reacted exclusively to the 271X peptide, and not with the
271R nor FIL peptides, was 5/12 RA sera, 0/18 healthy
sera, and 0/10 SLE sera. These results provide evidence that
antibodies in a subset of RA sera bind specifically to the
citrulline residue at position 271 of the FIBA alphaC
domain found in RA SF.
Discussion
Biomarker analysis consists of three phases: discovery,
verification, and validation [38, 39]. Discovery is per-
formed by a thorough analysis of a few samples with hopes
of identifying many candidate biomarkers to be used for





6. Ser299 -> G conflict
7. Ser304 -> G conflict
8. Gly317,Thr318 -> SG
9. Lys322, link to Gln41 in alpha-2- antiplasmin
10. Thr331 -> A
11. Gln347. link to Lys
12. Ser364, phosphorylation
13. Gln385, link to Lys
14. Asn406, methylated
15. Lys446 -> E
16. Ser453 glycosylation site
a. S -> N  
b. N-Linked (GLCNAC...)  
17. Thr456 -> A
18. Ser460, phosphorylation
19. Ser461 linked to Ser491
20. Ser491 linked to Ser461
21. Met495, oxidized
22. Lys527 linked to Gln
23. E545 -> V
24. Lys558 linked to Gln
25. Arg573 -> C
a. R -> L
26. Lys575 linked to Gln 
27. Ser576 phosphorylation
28. Ser577 phosporylation
29. Ser 578 phosphorylation
30. Lys581 linked to Gln
31. Arg591 cleavage site tryptase beta1
32. Lys599 linked to Gln
33. Splicing variant, DCDDVLQTHPSGTQ -> GIHTSPLGKPSLSP
34. Splicing variant, Missing
Fig. 4 (continued)
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Table 2 The sequence for the citrullinated peptide along with other fragments for which high-resolution MS and MS/MS spectra were obtained
z M(obs) M(pep) dM T Peptide aa# Mods 
2 1500.742 1500.74 0 F MELERPGGNEITR 259-271   
3 1516.743 1500.74 16 F MELERPGGNEITR 259-271 oxidation 
2 1344.644 1344.63 0 P MELERPGGNEIT 259-270   
2 1360.634 1344.63 16 P MELERPGGNEIT 259-270 oxidation 
4 3053.396 3054.39 1 F MELERPGGNEITRGGSTSYGTGSETESPR 259-287 citrullination 
3 3055.38 3054.39 1 F MELERPGGNEITRGGSTSYGTGSETESPR 259-287 citrullination 
2 1240.66 1240.66 0 P       LERPGGNEITR 261-271   
2 1240.66 1240.66 0 P       LERPGGNEITR 261-271   
3 2795.29 2794.31 1 P       LERPGGNEITRGGSTSYGTGSETESPR 261-287 citrullination 
2 1127.576 1127.57 0 P         ERPGGNEITR 262-271   
2 2398.044 2396.08 2 F               PGGNEITRGGSTSYGTGSETESPR 264-287 deamindation & citrullination
3 2423.088 2299.03 124 P                 GGNEITRGGSTSYGTGSETESPR 265-287 acetylation 
2 2071.926 2070.95 1 P                         EITRGGSTSYGTGSETESPR 268-287 citrullination 
3 2071.935 2070.95 1 P                         EITRGGSTSYGTGSETESPR 268-287 citrullination 
2 1571.67 1571.67 0 F                                  GGSTSYGTGSETESPR 272-287   
The dM indicates the nominal mass difference between the expected and observed mass for the unmodified precursor ion. Possible sites of post-
translational modification are indicated in red. Only citrullination of the Arg residue is consistent with the observed mass values and the failure of
trypsin to cleave at that site
Fig. 5 Electrospray mass spectra of the citrullinated FIBA 259–287 peptide. The upper spectrum shows the observed mass value for each of the
indicated charge states. The inset shows the isotope distribution for the 3+ charge state
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further study. Verification is performed by determining the
presence of select candidate biomarker in a large number of
clinical samples to estimate sensitivity and specificity.
Sensitivity is defined as the percentage of patients with
the specified disease that test positive for the biomarker.
Specificity is defined as the percentage of people that do
not have the specified disease that test negative for the
biomarker. Candidate biomarkers that have a high sensitiv-
ity and high specificity are further analyzed in the
validation phase. Validation is performed by analyzing the
presence of the candidates in a patient pool that is expected
to be present in a clinical setting where patients with the
specific disease will be diagnosed. The purpose of
validation is to test whether the candidate can be used for
diagnosis. After validation, the biomarkers may be used to
develop a diagnostic test. This study represents the
discovery phase of biomarker analysis.
We have used a proteomic method to fractionate RA SF
proteins, determine their reactivity to autoantibodies in RA
sera, and identify immunogenic antibody epitopes. This
method involves depletion of abundant serum proteins, two-
dimensional liquid chromatography, protein macroarrays
probed with RA and control sera to identify fractions
containing potential autoantigens, and mass spectrometric
analyses of those fractions via high-resolution LC–MS/MS.
We identified a portion of a SF protein, the fibrin alphaC
domain fragment, whose immunogenicity depended upon an
Arg to citrulline post-translational modification that had
occurred in vivo. We have shown that RA autoantibodies
specifically target an epitope containing citrulline at position
271 of FIBA and that this post-translational modification of
Arg 271 is present in RA SF. This approach is a feasible
strategy that can be used to identify or confirm other
autoantigens in RA SF as well as self-proteins that are targets
of autoreactive B cell responses in other autoimmune diseases.
Citrullinated fibrinogen is a known autoantigen in RA
[17, 40]. Experiments using purified fibrinogen and PAD
enzymes in vitro identified 22 possible citrullination sites
in FIBA [41, 42]; the Arg 271 identified in our study was
citrullinated by both PADI4 and PADI2 enzymes in vitro.
Several groups have reported reactivity of RA sera to
synthetic FIBA peptides [19, 43, 44] and fibrinogen
present in synovial exosomes [18]. Another report
showed that mAbs specific for the same citrullinated
FIBA peptide identified in our study detected the peptide
epitope’s presence in RA SF but not RA plasma [19]. The
results from our study confirm the presence and reactivity
Fig. 6 RA sera contain antibodies that specifically bind FIBA
peptides bearing a citrulline substitution at Arg 271. In an ELISA,
RA, SLE or control (C) sera were incubated with plate-immobilized
peptides corresponding to FIBA 259–287 with (271X) or without
(271R) a citrulline at position 271, or to filaggrin 619–631 (fil) with a
citrulline at position 625. Sera that reacted with 271R include: two out
of 18 normals, four out of 12 RA, one out of 10 SLE. Sera that reacted
with 271X include: two out of 18 normals, 10 out of 12 RA, one out
of 10 SLE. Sera that reacted with fil include: one out of 18 normals,
three out of 12 RA, one out of 10 SLE
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of citrullinated fibrin/fibrinogen in SF. If our study had
been performed using RA plasma as the source of
autoantigens, we would not have been successful at
identifying autoantigens. Identifying the best biomarker
source is crucial in biomarker discovery.
It is possible that our study failed to detect additional
immunogenic citrulline sites on FIBA as well as other
molecules. The failure of trypsin to cleave at citrulline
residues often results in large peptides that are difficult to
characterize by mass spectrometry. Other autoantigens
could be present at very low concentrations, lost due to
non-specific binding during chromatography, did not bind
to the nitrocellulose, did not bind in the right conformation
to the nitrocellulose, are heavily modified or glycosylated,
were undetected by the antibodies in the macroarrays, and/
or were not completely digested by trypsin. For these and
many more reasons, the proteins could have escaped
detection by the macroarray or mass spectrometry experi-
ments. This study was designed to identify proteins so if the
autoantigens are carbohydrate, lipid, or another type of
molecule then they would have also been undetected. The
chromatographs are more sensitive at detecting proteins
than the mass spectrometry. However, since small chroma-
tography peaks yielded no protein identifications, the nature
of the molecule that produced the peak is unknown.
The role for the fibrin alphaC domain fragment in RA
pathogenesis may be complex. Soluble citrullinated fibrin-
ogen and fibrin degradation products have been found in
RA SF but not RA plasma, suggesting that there are high
levels of active PAD enzymes in RA SF [19, 45]. Fibrin
deposits in the joints of RA patients are widely observed
and have been hypothesized to be the cause of pannus
formation [46]. The fibrin deposits in the joints allow the
fibrin molecules to remain in an inflammatory environment
for a prolonged period of time, which could facilitate post-
translational citrulline modification [5]. The alphaC domain
fragments are the first to be released during fibrinolysis so
they are constantly being generated [47]. If stably present,
such degraded alphaC fragments could readily be taken up
by antigen presenting cells and chronically displayed to the
immune system. Hence, a degradation product of an
aberrantly modified self-protein may be an RA autoantigen.
This discovery of post-translationally modified immu-
nogenic epitopes present on self-proteins in vivo may
contribute to improved diagnostic tests for RA. With the
data obtained from a limited number of patients, the
citrullinated 271X peptide seems to have similar sensitivity
(83.3%) as the commercially available CCP2 test. Since
antibodies to CCP have been shown to be present prior to
disease-onset development [11, 12], there is a possibility
that the citrullinated 271X peptide can also predict disease.
Studies determining when autoantibodies to the citrulli-
nated 271X are produced need to be conducted. Whether a
test using the native peptide offers any improvement over
the commercially available tests remains to be shown.
Irreversible joint damage can occur early in the disease
process [48], so early diagnosis and aggressive treatment is
vital to the preservation of joint function. Autoantibodies
specific for citrullinated epitopes are predominant in early
RA patients with high-grade joint inflammation and clinical
manifestations predicting development of severe erosive
disease [43, 49]. One promising diagnostic tool to define
clinically distinct subsets of RA patients is antigen micro-
array profiling of autoantibodies, an assay in which known
autoantigens are arrayed on slides, which are probed with
patient sera [43]. The method described here, which can be
used to identify epitopes on proteins that are modified in
inflamed synovial tissue in situ, will lead to additional
information about autoantigens that will help to increase the
power of such diagnostic autoantigen arrays.
In summary, proteomic analysis defined an immuno-
genic citrulline-containing epitope, within the fibrin
alphaC domain fragment, as an autoantigen present in
RA SF. This study provides further validation that
citrullinated fibrinogen is an autoantigen in RA. The
strategy used in this project should be useful for
identification of novel autoantigens in RA and other
autoimmune diseases.
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